

2011

1. Choi YP, Groner A, Ironside JW, Head MW. Comparison of the level, distribution and form of disease-associated prion protein in variant and sporadic Creutzfeldt-Jakob diseased brain using conformation-dependent immunoassay and Western blot. *J Gen Virol* 2011, 92(3): 727-32.
2. Heath CA, Cooper SA, Murray K, Lowman A, Henry C, Macleod MA, Stewart G, Zeidler M, Mackenzie JM, Knight RSG, Will RG. Diagnosing variant Creutzfeldt-Jakob disease: a retrospective analysis of the first 150 cases in the UK. *JNNP* 2011; 82: 646-651.
3. Heath C, Cooper SA, Murray K, Lowman A, Henry C, Macleod MA, Stewart GE, Zeidler M, Mackenzie JM, Ironside JW, Summers DM, Knight RSG, Will RG. Reply to Comment by Lukic et al on validation of diagnostic criteria for variant Creutzfeldt-Jakob disease. *Ann Neurol* 2011; 69(1):212.
4. Jansen C, Voet W, Head MW, Parchi P, Yull H, Verrips A, Wesseling P, Meulstee J, Baas F, van Gool WA, Ironside JW, Rozenmuller AJ. A novel seven-octapeptide repeat insertion in the prion protein gene (PRNP) in a Dutch pedigree with Gerstmann-Straussler-Scheinker disease phenotype: comparison with similar cases from the literature. *Acta Neuropathol* 2011; 121(1): 59-68.
5. Jones M, Peden AH, Head MW, Ironside JW. The application of in vitro cell-free conversion systems to human prion diseases. *Acta Neuropathol* 2011; 121(1): 135-43.
6. Krejciova Z, Pells C, Cancellotti E, Preile P, Bishop M, Samuel K, Barclay RG, Ironside JW, Manson JC, Turner ML, de Sousa P, Head MW. Human embryonic stem cells rapidly take up and then clear exogenous human and animal prions in vitro. *J Pathol* 2011; 223(5): 635-45.
7. Molesworth AM, Mackenzie J, Everington D, Knight RSG, Will RG. Sporadic Creutzfeldt-Jakob disease and risk of blood transfusion in the United Kingdom. *Transfusion* 2011; 51: 1872-1873.
8. Murray K. Creutzfeldt-Jakob disease mimics, or how to sort out the subacute encephalopathy patient. *Pract Neurol* 2011; 11(1): 19-28.
9. Petsch B, Muller-Schiffmann A, Lehle A, Zirdum E, Prikulis I, Kuhn F, Raeber AJ, Ironside JW, Korth C, Stitz L. Biological effects and use of PrP^{Sc} and PrP-specific antibodies generated by immunizing with purified full length native mouse prions. *J Virol* 2011, Feb 23 (Epub ahead of print).
10. Sherwood KR, Head MW, Walker R, Smith C, Ironside JW, Fazakerley JK. RNA integrity in post-mortem human vCJD and control brain tissue. *Neuropathol Appl Neurobiol* 2011; Jan 20 (Epub ahead of print).
11. Wadsworth JD, Dalmau-Mena I, Joiner S, Linehan JM, O'Malley C, Powell C, Brandner S, Asante EA, Ironside JW, Hilton DA, Collinge J. Effect of fixation on brain and lymphoreticular vCJD prions and bioassay of key positive

specimens from a retrospective vCJD prevalence study. *J Pathol* 2011; 223(4): 511-8.

12. Zaman SMA, Hill FGH, Palmer B, Millar CM, Bone A, Molesworth AM, Connor N, Lee CA, Dolan G, Wilde JT, Gill ON, Makris M. The risk of variant Creutzfeldt-Jakob disease among UK patients with bleeding disorders, known to have received potentially contaminated plasma products. *Haemophilia* 2011; 17(60): 931-937.

2010

13. Belay E, Schonberger LB, Brown P, Priola SA, Chesebro B, Will RG, Asher DM. Disinfection and sterilization of prion-contaminated medical instruments. *Infection Control and Hospital Epidemiology* 2010; 31(12):1304-1306.
14. Bishop MT, Will RG, Manson JC. Defining sporadic Creutzfeldt-Jakob disease strains and their transmission properties. *PNAS* 2010; 107 (26):12005-12010.
15. Chadeau-Hyam M, Clarke PS, Guihenneuc-Jouyau C, Cousens SN, Will RG, Ghani AC. An application of hidden Markov models to the French variant Creutzfeldt-Jakob disease epidemic. *Applied Statistics* 2010; 59 (5).
16. Chohan G, Llewelyn C, Mackenzie J, Cousens S, Kennedy A, Will RG, Hewitt P. Variant Creutzfeldt-Jakob disease in a transfusion recipient: coincidence or cause? *Transfusion* 2010; 50:1003-1006.
17. Chohan G, Pennington C, Mackenzie J, Andrews M, Everington D, Will RG, Knight RS, Green AJ. The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year review. *JNNP* 2010; 81 (11):1243-1248.
18. Choi YP, Peden AH, Groner A, Ironside JW, Head MW. Distinct stability states of disease-associated human prion protein identified by conformation-dependent immunoassay. *J Virol* 2010; 84(22): 12030-8.
19. Green A, Andrews M, Bishop M, Mackenzie J, McCord Y, Pennington C, Chohan G, Knight R. Elevated phosphorylated tau pT-181 in a possible *PRNP* codon 129 MV vCJD case. *JNNP* 2010; 81(11): 1243-8.
20. Head MW, Lowrie S, Chohan G, Knight R, Scoones DJ, Ironside JW. Variably protease-sensitive prionopathy in a *PRNP* codon 129 heterozygous UK patient with co-existing tau, α synuclein and A β pathology. *Acta Neuropathol* 2010; 120(6); 821-3.
21. Heath CA, Cooper SA, Murray K, Lowman A, Henry C, Macleod MA, Stewart GE, Zeidler M, Mackenzie JM, Ironside JW, Summers DM, Knight RS, Will RG. Validation of diagnostic criteria for variant Creutzfeldt-Jakob disease. *Ann Neurol* 2010; 67(6):761-770.
22. Ironside JW. Variant Creutzfeldt-Jakob disease. *Haemophilia* 2010; 5:175-180.

23. Jansen C, Head MW, van Gool WA, Bass F, Yull H, Ironside JW, Rozenmuller AJM. The first case of protease sensitive prionopathy (PSP^r) in the Netherlands: a patient with an unusual GSS-like clinical phenotype. *JNNP* 2010; 81(9): 1052-1055.
24. Knight R. Brain magnetic resonance studies in prion disease. *Nature Reviews Neurology* 2010; 6:10-11.
25. Knight R. The risk of transmitting prion disease by blood or plasma products. *Transfusion and Apheresis Science* 2010; 43:387-391.
26. Kovacs GG, Sanchez-Juan P, Strobel T, Schuur M, Poleggi A, Nocentini S, Giannattasio C, Belay G, Bishop M, Capellari S, Parchi P, Gelpi E, Gal A, Bakos A, Molnar MJ, Heinemann U, Zerr I, Knight RS, Mitrova E, van Duijn C, Budka H. Cathepsin D (C224T) polymorphism in sporadic and genetic Creutzfeldt-Jakob disease. *Alzheimer Disease Assoc Disord* 2010; 24(1):104-107.
27. Millar CM, Connor N, Dolan G, Lee CA, Makris M, Wilde J, Winter M, Ironside JW, Gill N, Hill FG. Risk reduction strategies for variant Creutzfeldt-Jakob disease transmission by UK plasma products and their impact on patients with inherited bleeding disorders. *Haemophilia* 2010; 16(2):305-315.
28. Molesworth A, Cousens SN, Gill ON, Ward HJT, on behalf of the local investigation teams. Variant Creutzfeldt-Jakob disease in the United Kingdom? a countrywide or local risk? *J Epidemiol Community Health* 2010; 64:616-621.
29. Murray K, Peters J, Stellitano L, Winstone A, Verity C, Will R. Is there evidence of vertical transmission of variant CJD? *JNNP* 2010; (Epub ahead of print).
30. Peden A, McCardle L, Head MW, Love S, Ward HJT, Cousens SN, Keeling DM, Millar CM, Hill FGH, Ironside JW. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. *Haemophilia* 2010; 16:296-304.
31. Verity C, Winstone AM, Stellitano L, Will R, Nicoll A. The epidemiology of progressive intellectual and neurological deterioration in childhood. *Arch Dis Child* 2010; 95(5):361-364.
32. Verity CM, Winstone AM, Stellitano L, Krishnakumar D, Will R, McFarland R. The clinical presentation of mitochondrial diseases in children with progressive intellectual and neurological deterioration: a national, prospective, population-based study. *Developmental Medicine & Child Neurology* 2010; 52(5):434-440.
33. Will B. Variant CJD: where has it gone, or has it? *Practical Neurology* 2010; 10:250-251.

2009

34. Armitage W J, Tullo AB, Ironside JW. Risk of Creutzfeldt-Jakob disease transmission by ocular surgery and tissue transplantation. *Eye (Lond)* 2009; 23(10): 1926-30.

35. Armstrong RA, Ironside JW, Lantos PL, Cairns NJ. A quantitative study of the pathological changes in the cerebellum in 15 cases of variant Creutzfeldt-Jakob disease (vCJD). *Neuropathol Appl Neurobiol* 2009; 35(1): 36-45.
36. Barr JB, Watson M, Head MW, Ironside JW, Harris N, Hogarth C, Fraser JR, Barron R. Differential protein profiling as a potential multi-marker approach for TSE diagnosis. *BMC Infectious Diseases* 2009; 9:188.
37. Bird SM, Merrall ELC, Ward HJT, Will RG. Survival and re-operation rates after neurosurgical procedures in Scotland: implications for targeted surveillance of sub-clinical variant Creutzfeldt-Jakob disease. *Neuroepidemiology* 2009; 33: 1-11.
38. Bishop M, Pennington C, Heath CA, Will RG, Knight RSG. PRNP variation in UK sporadic and variant Creutzfeldt-Jakob disease highlights genetic risk factors and a novel non-synonymous polymorphism. *BMC Medical Genetics* 2009; 10:146:doi:10.1186/1471-2350-10-146.
39. Brandel J-P, Heath CA, Head MW, Leevavasseur E, Knight R, Laplanche JL, Langeveld JP, Ironside JW, Hauw J-J, Mackenzie J, Alperovitch A, Will RG, Haik S. Variant Creutzfeldt-Jakob disease in France and the United Kingdom: evidence for the same agent strain. *Ann Neurol* 2009; 65(3): 249-256.
40. Clewley JP, Kelly CM, Andrews N, Vogliqi K, Mallinson G, Kaisar M, Hilton DA, Ironside JW, Edwards P, McCardle LM, Ritchie DL, Dabaghian R, Ambrose HE, Gill ON. Prevalence of disease related prion protein in anonymous tonsil specimens in Britain: cross sectional opportunistic survey. *BMJ* 2009; 338: b1442.
41. Gillies M, Chohan G, Llewelyn CA, Mackenzie J, Ward HJT, Hewitt PE, Will RG. A retrospective case note review of deceased recipients of vCJD-implicated blood transfusions. *Vox Sanguinis* 2009; 97: 211-218.
42. Hawkins K, Chohan G, Kipps C, Will R, Kapur N. Variant Creutzfeldt-Jakob disease: neuropsychological profile in an extended series of cases. *J Int Neuropsychol Soc* 2009; 15:807-810.
43. Head MW, Knight R, Zeidler M, Yull H, Barlow A, Ironside JW. A case of protease sensitive prionopathy in a patient in the UK. *Neuropathol and Appl Neurobiol* 2009; 35: 628-632.
44. Head MW, Ironside JW. Sporadic Creutzfeldt-Jakob disease: discrete subtypes or a spectrum of disease? *Brain* 2009; 132: 2627-2629.
45. Head MW, Yull HM, Ritchie DL, Bishop MT, Ironside JW. Pathological investigation of the first blood donor and recipient pair linked by transfusion-associated variant Creutzfeldt-Jakob disease transmission. *Neuropathol and Appl Neurobiol* 2009; 35(4):433-436.
46. Hilton DA, Head MW, Singh VK, Bishop M, Ironside JW. Familial prion disease with a novel serine to isoleucine mutation at codon 132 of prion protein gene (*PRNP*). *Neuropathol Appl Neurobiol* 2009; 35: 111-115.
47. Hizume M, Kobayashi A, Teruya K, Ohashi H, Ironside JW, Mohri S, Kitamoto T. Human prion protein (PrP) 219K is converted to PrP^{Sc} but shows

- heterozygous inhibition in variant Creutzfeldt-Jakob disease infection. *J Biol Chem.* 2009; 284(6): 3603-9.
48. Jansen C, Head MW, Rozenmuller AJ, Ironside JW. Panencephalopathic Creutzfeldt-Jakob disease in the Netherlands and the UK: clinical and pathological characteristics of nine patients. *Neuropathol and Appl Neurobiol* 2009; 35(3): 272-282.
 49. Jones M, Peden AH, Yull H, Wight D, Bishop MT, Prowse CV, Turner ML, Ironside JW, MacGregor IR, Head MW. Human platelets as a substrate source for the in vitro amplification of the abnormal prion protein (PrP) associated with variant Creutzfeldt-Jakob disease. *Transfusion.* 2009; 49(2): 376-84.
 50. Jones M, McLoughlin V, Connolly JG, Farquhar CF, Macgregor IR, Head MW. Production and characterization of a panel of monoclonal antibodies against native human cellular prion protein. *Hybridoma (Larchmt)* 2009; 28(1): 13-20.
 51. Jones M, Wight D, McLoughlin V, Norrby K, Ironside JW, Connolly JG, Farquhar CF, MacGregor IR, Head MW. An antibody to the aggregated synthetic prion protein peptide (PrP106-126) selectively recognizes disease-associated prion protein (PrP) from human brain specimens. *Brain Pathol.* 2009; 19(2): 293-302.
 52. Jones M, Wight D, Barron R, Jeffrey M, Manson J, Prowse C, Ironside JW, Head MW. Molecular model of prion transmission to humans. *Emerging Infectious Diseases* 2009; 15(12): 2013-2016.
 53. Kaski D, Mead S, Hyare H, Cooper S, Jampana R, Overell J, Knight R, Collinge J, Rudge P. Variant CJD in an individual heterozygous for *PRNP* codon 129. *Lancet* 2009; 374: 2128.
 54. Knight RSG, Ward HJT. The transmissible spongiform encephalopathies. In: Detels R, Beaglehole R, Lansang MA, Gulliford M, editors. *Oxford Textbook of Public Health.* Oxford: Oxford University Press, 2009: 1160-1172.
 55. Ladogana A, Sanchez-Juan P, Mitrova E, Green A, Cuadrado-Corrales N, Sanchez-Valle R, Koscova S, Aguzzi A, Sklaviadis T, Kulczycki J, Gawinecka J, Saiz A, Calero M, van Duijn CM, Pocchiarri M, Knight R, Zerr I. Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies. *J Neurol* 2009; 256: 1620-1628.
 56. Meissner B, Kallenberg K, Sanchez-Juan P, Collie D, Summers DM, Almonti S, Collins SJ, Smith P, Cras P, Jansen GH, Brandel JP, Coulthart MB, Roberts H, van Everbroeck B, Galanaud D, Mellina V, Will RG, Zerr I. MRI lesion profiles in sporadic Creutzfeldt-Jakob disease. *Neurology* 2009; 72: 1994-2001.
 57. Parchi P, Notari S, Weber P, Schimmel H, Budka H, Ferrer I, Haik S, Hauw JJ, Head MW, Ironside JW, Limido L, Rodriguez A, Ströbel T, Tagliavini F, Kretschmar HA. Inter-laboratory assessment of PrPSc typing in Creutzfeldt-Jakob disease: a Western blot study within the NeuroPrion Consortium. *Brain Pathol.* 2009; 19(3): 384-91.

58. Pennington C, Chohan G, Mackenzie J, Andrews M, Will R, Knight R, Green A. The role of cerebrospinal fluid proteins as early diagnostic markers for sporadic Creutzfeldt-Jakob disease. *Neurosci Lett* 2009; 455(1): 56-59.
59. Ritchie DL, Boyle A, McConnell I, Head MW, Ironside JW, Bruce ME. Transmissions of variant Creutzfeldt-Jakob disease from brain and lymphoreticular tissue show uniform and conserved bovine spongiform encephalopathy-related phenotypic properties on primary and secondary passage in wild-type mice. *J Gen Virol* 2009; 90 (12): 3075-3082.
60. Sikorska B, Liberski PP, Sobow T, Budka H, Ironside JW. Ultrastructural study of florid plaques in variant Creutzfeldt-Jakob disease: a comparison with amyloid plaques in kuru, sporadic Creutzfeldt-Jakob disease and Gerstmann-Straussler-Scheinker disease. *Neuropathol Appl Neurobiol* 2009; 35(1): 46-59.
61. Verity CM, Winstone A, Stellitano L, Krishnakumar D, Will R, McFarland R. The clinical presentation of mitochondrial diseases in children with progressive intellectual and neurological deterioration: a national, prospective, population-based study. *Developmental Medicine & Child Neurology* 2009; doi: 10.1111/j.1469-8749.2009.03463.x.
62. Ward HJT, Mackenzie JM, Llewelyn CA, Knight RSG, Hewitt PE, Connor N, Molesworth A, Will RG. Variant Creutzfeldt-Jakob disease and exposure to fractionated plasma products. *Vox Sanguinis* 2009; 97; 207-210.
63. Ward H, Knight R. Transmissible spongiform encephalopathy and meat safety. In: Toldra F, editor. *Safety of Meat and Processed Meat (Food Microbiology and Food Safety Series)*. New York: Springer, 2009: 125-146.
64. Yull HM, Ironside JW, Head MW. Further characterisation of the prion protein molecular types detectable in the NIBSC Creutzfeldt-Jakob disease brain reference materials. *Biologicals* 2009; 37(4): 210-5.
65. Zerr I, Kallenberg K, Summers DM, Romero C, Taratuto A, Heinemann U, Breithaupt M, Varges D, Meissner B, Ladogana A, Schuur M, Haik S, Collins SJ, Jansen GH, Stokin GB, Pimentel J, Hewer E, Collie D, Smith P, Roberts H, Brandel JP, van Duyn C, Pocchiari M, Begue C, Cras P, Will RG, Sanchez-Juan P. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. *Brain* 2009; 132(10): 2659-68.

2008

66. Bishop MT, Kovacs GG, Sanchez-Juan P, Knight RSG. Cathepsin D SNP associated with increased risk of variant Creutzfeldt-Jakob disease. *BMC Medical Genetics* 2008; 9: 31.
67. Bishop MT, Ritchie DL, Will RG, Ironside JW, Head MW, Thomson V, Bruce M, Manson JC. No major change in vCJD agent strain after secondary transmission via blood transfusion. *PLoS One*. 2008; 3(8): e2878.

68. Bone I, Belton L, Walker AS, Darbbysshire J. Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. *European J Neurology* 2008; 15: 458-64.
69. Heath CA, Will RG. Clinical aspects of variant Creutzfeldt-Jakob disease. In: Duyckaerts C, ed. *Handbook of Clinical Neurology, Vol 89 (3rd series) Dementias*. Amsterdam: Elsevier B.V. 2008: 765-78.
70. Jones M, Peden AH, Wight D, Prowse C, Macgregor I, Manson J, Turner M, Ironside JW, Head MW. Effects of human PrPSc type and PRNP genotype in an in-vitro conversion assay. *Neuroreport*. 2008; 19(18): 1783-6.
71. Knight R. Clinical features and diagnosis of human prion diseases. *Future Neurology* 2008; 3(4): 473-481.
72. Krasnianski A, Kallenberg K, Collie DA, Meissner B, Schulz-Schaeffer WJ, Heinemann U, Vargas D, Summers DM, Kretzschmar HA, Talbot T, Will RG, Zerr I. MRI in the classical MM1 and the atypical MV2 subtypes of sporadic CJD: an inter-observer agreement study. *Eur J Neurol* 2008; 15: 762-71.
73. Murray K, Ritchie DL, Bruce M, Young CA, Doran M, Ironside JW, Will RG. Sporadic Creutzfeldt-Jakob disease in two adolescents. *JNNP* 2008; 79(1): 14-8.
74. Stewart LA, Rydzewska LHM, Keogh GF, Knight RSG. Systematic review of therapeutic interventions in human prion disease. *Neurology* 2008; 70: 1272-81.
75. Uro-Coste E, Cassard H, Simon S, Lugan S, Bilheude JM, Perret-Liaudet A, Ironside JW, Haik S, Basset-Leobon C, Lacroux C, Peoch' K, Streichenberger N, Langeveld J, Head MW, Grassi J, Hauw JJ, Schelcher F, Delisle MB, Andréoletti O. Beyond PrP9res) type 1/type 2 dichotomy in Creutzfeldt-Jakob disease. *PLoS Pathog*. 2008; 4(3): e1000029.
76. Ward HJT, Everington D, Cousens SN, Smith-Bathgate B, Gillies M, Murray K, Knight RSG, Smith PG, Will RG. Risk factors for sporadic Creutzfeldt-Jakob disease. *Ann Neurol* 2008; 63: 347-54.
77. Ward HJT, Knight RSG. Surgery and risk of sporadic Creutzfeldt-Jakob disease. *Neuroepidemiology* 2008; 31; 241-242.
78. Will RG. Cold comfort pharm. *Practical Neurology* 2008; 8: 60-61.
79. Will RG. Bovine Spongiform Encephalopathy. In: Mahy BWJ, van Regenmortel MHV, eds. *Encyclopedia of Virology*. Oxford: Elsevier 2008: 368-74.

2007

80. Bathgate-Smith B, Chohan G, Knight R. Keeping watch over the development of CJD. *British Journal of Neuroscience Nursing* 2007; 3(8): 357-359.
81. Bruce ME, Will RG, Ironside JW, Fraser H. Evidence for a link between variant Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. In:

- Hornlimann B, Riesner D, Kretzschmar H, editors. Prions in Humans and Animals. Berlin: Walter de Gruyter GmbH & Co; 2007. p. 573-8
82. Clarke P, Will RG, Ghani AC. Is there the potential for an epidemic of variant Creutzfeldt-Jakob disease via blood transfusion in the UK? *J R Soc Interface* 2007.
 83. Everington D, Smith AJ, Ward HJT, Letters S, Will RG, Bagg J. Dental treatment and risk of variant CJD - a case control study. *British Dental Journal* 2007; 202(8):E19.
 84. Fagge TJ, Barclay GR, Stove GC, Stove G, Robinson MJ, Head MW, Ironside JW, Turner ML. Application of atomic dielectric resonance spectroscopy for the screening of blood samples from patients with clinical variant and sporadic CJD. *J Transl Med* 2007; 5:41.
 85. Green A, Sanchez-Juan P, Ladogana A, Cuadrado-Corrales N, Sanchez-Valle R, Mitrova E, Stoeck K, Sklaviadis T, Kulczycki J, Heinemann U, Hess K, Slivarichova D, Saiz A, Calero M, Mellina V, Knight R, van Duijn CM, Zerr I. CSF analysis in patients with sporadic CJD and other transmissible spongiform encephalopathies. *Eur J Neurol* 2007; 14:121-124.
 86. Head MW, Ironside JW. vCJD and the gut: implications for endoscopy. *Gut* 2007; 56(1): 9-11.
 87. Hilton-Jones D, Ironside JW, Simpson DJ. A young man with rapidly progressive multifocal disease affecting the white matter. *Pract Neurol* 2007; 7(3): 172-81.
 88. Hornlimann B, Kretzschmar H, Will RG, Windl O, Budka H. Introduction to Surveillance for Human Prion Diseases. In: Hornlimann B, Riesner D, Kretzschmar H, editors. Prions in Humans and Animals. Berlin: Walter de Gruyter GmbH & Co; 2007. p. 339-46.
 89. Hornlimann B, Riesner D, Kretzschmar H, Will RG, MacDiarmid SC, Wells GAH et al. Historical Introduction. In: Hornlimann B, Riesner D, Kretzschmar H, editors. Prions in Humans and Animals. Berlin: Walter de Gruyter GmbH & Co; 2007. p. 3-27.
 90. Ironside JW, Bell JE. Infective dementias. *Panminerva Med* 2007; 49(4): 209-25.
 91. Jones M, Peden AH, Prowse CV, Groner A, Manson JC, Turner ML, Ironside JW, MacGregor IR, Head MW. In vitro amplification and detection of variant Creutzfeldt-Jakob disease PrP^{Sc}. *J Pathol* 2007; 213(1): 21-6.
 92. Millar T, Walker R, Arango JC, Ironside JW, Harrison DJ, MacIntyre DJ, Blackwood D, Smith C, Bell JE. Tissue and organ donation for research in forensic pathology: the MRC Sudden Death Brain and Tissue Bank. *J Pathol* 2007; 213(4): 369-75.
 93. Murray K, Will RG. Prion Diseases. In: Schapira AHV, Byrne E, DiMauro S, Frackowiak RSJ, Johnson RT, Mizuno Y et al., editors. Neurology and Clinical Neurosciences. Philadelphia: Mosby Elsevier; 2007. p. 1297-302.

94. Peden AH, Ritchie DL, Uddin HP, Dean AF, Schiller KA, Head MW, Ironside JW. Abnormal prion protein in the pituitary in sporadic and variant Creutzfeldt-Jakob disease. *J Gen Virol* 2007; 88: 1068-72.
95. Sanchez-Juan P, Houben MP, Hoff JL, Jansen C, Sie MP, van Rijn MJ, Ironside JW, Will RG, van Duijn CM, Rozemuller A. The first case of variant Creutzfeldt-Jakob disease in The Netherlands. *J Neurol* 2007; 254(7): 958-60.
96. Sanchez-Juan P, Cousens SN, Will RG, van Duijn CM. Source of variant Creutzfeldt-Jakob disease outside United Kingdom. *Emerging Infectious Diseases* 2007; 13:1166-1169.
97. Sanchez-Juan P, Bishop MT, Green A, Giannattasio C, Arias-Vasquez A, Poleggi A, Knight RSG, van Duijn CM. No evidence for association between *tau* gene haplotypic variants and susceptibility to Creutzfeldt-Jakob disease. *BMC Medical Genetics* 2007; 8: 77.
98. St Rose SG, Hunter N, Foster JD, Drummond D, McKenzie C, Parnham D, Will RG, Woolhouse MEJ, Rhind SM. Quantification of Peyer's patches in Cheviot sheep for future scrapie pathogenesis studies. *Veterinary Immunology and Immunopathology* 2007; 116:163-171.
99. Sturzenegger M, Will RG. Clinical findings in human prion diseases. In: Hornlimann B, Riesner D, Kretschmar H, editors. *Prions in Humans and Animals*. Berlin: Walter de Gruyter GmbH & Co; 2007. p. 347-62.
100. Tennent GA, Head MW, Bishop M, Hawkins PN, Will RG, Knight R, Peden AH, McCardle LM, Ironside JW, Pepys MB. Disease-associated prion protein is not detectable in human systemic amyloid deposits. *J Pathol* 2007; 213(4): 376-83.
101. Will RG, Knight RSG. The European surveillance system for Creutzfeldt-Jakob disease. *CJD Support Network Newsletter* 2007; 16:1-5.
102. Will RG. Priony a verejne zdravotnictvo. *Neurologie Pro Praxi* 2007; 3:84-86.
103. Will RG, Ironside JW. Portrait of variant Creutzfeldt-Jakob disease. In: Hornlimann B, Riesner D, Kretschmar H, editors. *Prions in Humans and Animals*. Berlin: Walter de Gruyter GmbH & Co; 2007. p. 204-9.
104. Williams L, Brown P, Ironside J, Gibson S, Will R, Ritchie D, Kreil TR, Abec C. Clinical, neuropathological and immunohistochemical features of sporadic and variant forms of Creutzfeldt-Jakob disease in the squirrel monkey (*Saimiri sciureus*). *J Gen Virol* 2007; 88: 688-95.

2006

105. Armstrong RA, Cairns NJ, Ironside JW. Size frequency distributions of the florid prion protein aggregates in variant Creutzfeldt-Jakob disease follow a power-law function. *Neurol Sci* 2006; 27(2): 104-9.

106. Asano M, Mohri S, Ironside JW, Ito M, Tamaoki N, Kitamoto T. vCJD prion acquires altered virulence through trans-species infection. *Biochem Biophys Res Commun* 2006; 342(1): 293-9.
107. Binelli S, Agazzi P, Giaccone G, Will RG, Bugiani O, Franceschetti S, Tagliavini F. Periodic electroencephalogram complexes in a patient with variant Creutzfeldt-Jakob disease. *Ann Neurol* 2006; 59:423-427.
108. Bishop MT, Will RG, Manson JC. T-cell immunity and prion-protein 129 polymorphism in vCJD - author's reply. *Lancet Neurology* 2006; 5:555.
109. Bishop MT, Hart P, Aitchison L, Baybutt HN, Plinston C, Thomson V, Tuzi NL, Head MW, Ironside JW, Will RG, Manson JC. Predicting susceptibility and incubation time of human to human transmission of vCJD. *Lancet Neurology* 2006; 5:393-398.
110. Boesenberg-Grosse C, Schulz-Schaeffer WJ, Bodemer M, Ciesielczyk B, Meissner B, Krasnianski A, Bartl M, Heinemann U, Varges D, Eigenbrod S, Kretzschmar HA, Green A, Zerr I. Brain-derived proteins in the CSF: do they correlate with brain pathology in CJD? *BMC Neurol* 2006; 6: 35.
111. Brazier MW, Lewis V, Ciccotosto GD, Klug GM, Lawson VA, Cappai R, Ironside JW, Masters CL, Hill AF, White AR, Collins S. Correlative studies support lipid peroxidation is linked to PrP(res) propagation as an early primary pathogenic event in prion disease. *Brain Res Bull* 2006; 68(5): 346-54.
112. Cancellotti E, Barron RM, Bishop MT, Hart P, Wiseman F, Manson JC. The role of host PrP in Transmissible Spongiform Encephalopathies. *Biochim Biophys Acta* 2006 (online publication).
113. Collins SJ, Sanchez-Juan P, Masters CL, Klug GM, van Duijn C, Poggi A, Pocchiari M, Almonti S, Cuadrado-Corrales N, de Pedro Cuesta J, Budka H, Gelpi E, Glatzel M, Tolnay M, Hewer E, Zerr I, Heinemann U, Kretzschmar HA, Jansen GH, Olsen E, Mitrova E, Alperovitch A, Brandel J-P, Mackenzie J, Murray K, Will RG. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. *Brain* 2006; 129:2278-2287.
114. Cooper SA, Murray KL, Heath CA, Will RG, Knight RSG. Sporadic Creutzfeldt-Jakob disease with cerebellar ataxia at onset in the United Kingdom. *JNNP* 2006; 77:1273-1275.
115. Garske T, Ward HJT, Clarke P, Will RG, Ghani AC. Factors determining the potential for onward transmission of variant Creutzfeldt-Jakob disease via surgical instruments. *J R Soc Interface* 2006; 3:757-766.
116. Goodall CA, Head MW, Everington D, Ironside JW, Knight RS, Green AJ. Raised CSF phospho-tau concentrations in variant Creutzfeldt-Jakob disease: diagnostic and pathological implications. *JNNP* 2006; 77(1): 89-91.
117. Head MW, Ironside JW. Sporadic Creutzfeldt-Jakob disease: further twists and turns in a convoluted protein. *Brain* 2006; 129: 2238-40.

118. Heath CA, Barker RA, Esmonde TFG, Harvey P, Trend P, Head MW, Smith C, Bell JE, Ironside JW, Will RG, Knight RSG. Dura mater-associated Creutzfeldt-Jakob disease: experience from surveillance in the UK. *JNNP* 2006; 77:880-882.
119. Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. Three reported cases of variant Creutzfeldt-Jakob disease transmission following transfusion of labile blood components. *Vox Sang* 2006; 91:348.
120. Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiology Review study. *Vox Sang* 2006; 91:221-230.
121. Ironside JW, Bishop MT, Connolly K, Hegazy D, Lowrie S, Le Grice M, Ritchie DL, McCardle LM, Hilton DA. Variant Creutzfeldt-Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study. *BMJ* 2006; 332:1186-1188.
122. Ironside JW. Variant Creutzfeldt-Jakob disease: risk of transmission by blood transfusion and blood therapies. *Haemophilia* 2006; 12 Suppl 1: 8-15; discussion 26-28.
123. Knight R, Stanley S, Wong M, Dolan G. Hemophilia therapy and blood-borne pathogen risk. *Seminars in Thrombosis and Hemostasis* 2006; 32 Suppl 2:3-9.
124. Knight R. Creutzfeldt-Jakob disease: a rare cause of dementia in elderly persons. *Clin Infect Dis* 2006; 43 (3):340-346.
125. Lourenco P, Schmerr MJ, MacGregor I, Will RG, Ironside JW, Head MW. Application of an immunocapillary electrophoresis assay to the detection of abnormal prion protein in brain, spleen and blood specimens from patients with variant Creutzfeldt-Jakob disease. *J Gen Virol* 2006; 87:3119-3124.
126. Manson JC, Cancellotti E, Hart P, Bishop MT, Barron RM. The transmissible spongiform encephalopathies: emerging and declining epidemics. *Biochem Soc Trans* 2006; 34(6): 1155-8.
127. Peden AH, Ritchie DL, Head MW, Ironside JW. Detection and localization of PrP^{Sc} in the skeletal muscle of patients with variant, iatrogenic and sporadic forms of Creutzfeldt-Jakob disease. *Am J Pathol* 2006; 168(3): 927-35.
128. Sanchez-Juan P, Green A, Ladogana A, Cuadrado-Corrales N, Sanchez-Valle R, Mitrova E, Stoeck K, Sklaviadis T, Kulczycki J, Hess K, Bodemer M, Slivarichova D, Saiz A, Calero M, Ingrosso L, Knight R, Janssens ACJW, van Duijn CM, Zerr I. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. *Neurology* 2006; 67(4):637-643.
129. Sasaki K, Doh-ura K, Ironside J, Mabbott N, Iwaki T. Clusterin expression in follicular dendritic cells associated with prion protein accumulation. *J Pathol* 2006; 209(4): 484-91.
130. St Rose SG, Hunter N, Matthews L, Foster JD, Chase-Topping ME, Kruuk LE, Shaw DJ, Rhind SM, Will RG, Woolhouse ME. Comparative evidence for a link

between Peyer's patch development and susceptibility to transmissible spongiform encephalopathies. *BMC Infect Dis* 2006; 6: 5.

131. Tullo AB, Buckley RJ, Kelly T, Head MW, Bennett P, Armitage WJ, Ironside JW. Transplantation of ocular tissue from a donor with sporadic Creutzfeldt-Jakob disease. *Clin Experiment Ophthalmol* 2006; 34(7): 645-9.
132. Ward HJ. Evidence of a new human genotype susceptible to variant CJD. *Euro Surveill* 2006; 11(6): E060601.3.
133. Ward HJT, Everington D, Cousens SN, Smith-Bathgate B, Leitch M, Cooper S, Heath C, Knight RSG, Will RG. Risk factors for variant Creutzfeldt-Jakob disease: a case-control study. *Ann Neurol* 2006; 59:111-120.
134. Whittle IR, Knight RSG, Will RG. Unsuccessful intraventricular pentosan polysulphate treatment of variant Creutzfeldt-Jakob disease. *Acta Neurochir (Wien)* 2006; 148:677-679.
135. Yull HM, Ritchie DL, Langeveld JPM, van Zijderveld FG, Bruce ME, Ironside JW, Head MW. Detection of Type 1 prion protein in variant Creutzfeldt-Jakob disease. *Am J Pathol* 2006; 168(1):151-157.

2005

136. Armstrong RA, Cairns NJ, Ironside JW, Lantos PL. Size frequency distribution of prion protein (PrP) aggregates in variant Creutzfeldt-Jakob disease (vCJD). *J Neural Transm* 2005; 112(11): 1565-1573.
137. Bramble MG, Ironside J. Variant Creutzfeldt-Jakob disease: update. *Gut* 2005; 54(1): 170.
138. Cooper SA, Heath CA, Will RG, Knight RSG. Visual loss at onset of sporadic Creutzfeldt-Jakob disease: making sense of the "Heidenhain variant". *JNNP* 76(1), 156. 2005.
139. Cooper SA, Will RG, Knight RSG. Sporadic Creutzfeldt-Jakob disease identified only at autopsy: why are cases missed in life? *JNNP* 76(9), 1318. 2005.
140. Cooper SA, Murray KL, Heath CA, Will RG, Knight RSG. Isolated visual symptoms at onset in sporadic Creutzfeldt-Jakob disease: the clinical phenotype of the "Heidenhain variant". *Br J Ophthalmol* 2005; 89:1341-1342.
141. Fagge T, Barclay GR, MacGregor I, Head M, Ironside J, Turner M. Variation in concentration of prion protein in the peripheral blood of patients with variant and sporadic Creutzfeldt-Jakob disease detected by dissociation enhanced lanthanide fluoroimmunoassay and flow cytometry. *Transfusion* 2005; 45(4):504-513.
142. Farrugia A, Ironside JW, Giangrande P. Variant Creutzfeldt-Jakob disease transmission by plasma products: assessing and communicating risk in an era of scientific uncertainty. *Vox Sang* 2005; 89: 186-192.

143. Head MW, Kouverianou E, Taylor L, Green A, Knight R. Evaluation of urinary PrPsc as a diagnostic test for sporadic, variant and familial CJD. *Neurology* 2005; 64:1794-1796.
144. Head MW, Peden AH, Yull HM, Ritchie D, Bonshek RE, Tullo AB, Ironside JW. Abnormal prion protein in the retina in the most commonly occurring subtype of sporadic Creutzfeldt-Jakob disease. *Br J Ophthalmol* 2005; 89: 1131-33.
145. Head MW, Ironside JW. Mad cows and monkey business: the end of vCJD? *Lancet* 2005; 365: 730-31.
146. Heath CA, Murray KL, Yull HM, Head M, Will RG, Knight RSG. Creutzfeldt-Jakob disease associated with human dura mater - experience from UK surveillance. *JNNP* 76(9), 1318. 2005.
147. Heath CA, Cooper SA, Murray K, Everington D, Smith-Bathgate B, Leitch M, Smith P, Cousens SN, Knight RSG, Will RG, Ward HJT. A case control study investigating dietary risk factors for variant CJD. *JNNP* 76(1), 150. 2005.
148. Ironside JW, Ritchie DL, Head MW. Phenotypic variability in human prion diseases. *Neuropathol Appl Neurobiol* 2005; 31(6):565-579.
149. Jones M, Head MW, Connolly JG, Farquhar CF, Hornsey VS, Pepper DS, MacGregor IR. Purification of normal cellular prion protein from human platelets and the formation of a high molecular weight prion protein complex following platelet activation. *Biochem Biophys Res Commun* 2005; 335: 48-56.
150. Knight R. Clinical Aspects of Variant CJD. In: Kitamoto T, editor. *Prions: Food and Drug Safety*. Tokyo: Springer-Verlag, 2005: 15-30.
151. Kobayashi A, Satoh S, Ironside JW, Mohri S, Kitamoto T. Type 1 and Type 2 human PrPsc have different aggregation sizes in methionine homozygotes with sporadic, iatrogenic and variant Creutzfeldt-Jakob disease. *J Gen Virol* 2005; 86:237-240.
152. Kovacs GG, Puopolo M, Ladogana A, Pocchiari M, Budka H, van Duijn C, Collins SJ, Boyd A, Giulivi A, Coulthard M, Delasnerie-Laupretre N, Brandel J-P, Zerr I, Kretzschmar HA, Pedro Cuesta J, Calero-Lara M, Glatzel M, Aguzzi A, Bishop M, Knight RSG, Belay G, Will R, Mitrova E. Genetic prion disease: the EURO-CJD experience. *Hum Genet* 2005; 118:166-174.
153. Kovacs GG, Laszlo L, Bakos A, Minarovits J, Bishop MT, Strobel T, Vajna B, Mitrova E, Majtenyi K. Increased incidence of genetic human prion disease in Hungary. *Neurology* 2005; 65: 1666-69.
154. Ladogana A, Puopolo M, Croes EA, Budka H, Jarius C, Collins S, Klug GM, Sutcliffe T, Giulivi A, Alperovitch A, Delasnerie-Laupretre N, Brandel J-P, Poser S, Kretzschmar H, Rietvald I, Mitrova E, de Pedro Cuesta J, Martinez-Martin P, Glatzel M, Aguzzi A, Knight R, Ward H, Pocchiari M, van Duijn CM, Will RG, Zerr I. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. *Neurology* 2005; 64:1586-1591.

155. Murray KL, Knight RSG, Summers D, Collie DAC, Will RG. The role of MRI brain scan in the diagnosis of human prion disease. *JNNP* 76(4), 608. 2005.
156. Murray KL. Vertical transmission of variant CJD. *JNNP* 2005; 76(9): 1318 .
157. Pan T, Li RL, Kang SC, Pastore M, Wong BS, Ironside J, Gambetti P, Sy MS. Biochemical fingerprints of prion diseases: scrapie prion protein in human prion diseases that share prion genotype and type. *J Neurochem* 2005; 92(1):132-142.
158. Pan T, Li R, Wong B-S, Kang S-C, Ironside J, Sy M-S. Novel antibody-lectin enzyme-linked immunosorbent assay that distinguishes prion proteins in sporadic and variant cases of Creutzfeldt-Jakob disease. *J Clin Microbiol* 2005; 43(3):1118-1126.
159. Peden AH, Ritchie DL, Ironside JW. Risks of transmission of variant Creutzfeldt-Jakob disease by blood transfusion. *Folia Neuropathol* 2005; 43:271-278.
160. Petersen RB, Siedlak SL, Lee HG, Kim YS, Nunomura A, Tagliavini F, Ghetti B, Cras P, Moreira PI, Castellani RJ, Guentchev M, Budka H, Ironside JW, Gambetti P, Smith MA, Perry G. Redox metals and oxidative abnormalities in human prion diseases. *Acta Neuropathologica* 2005; 110(3):232-238.
161. Smith-Bathgate B. Creutzfeldt-Jakob disease: diagnosis and nursing care issues. *Nursing Times* 2005; 101(20): 52-53.
162. Soto C, Andreas L, Suardi S, Cardone F, Castilla J, Frossard MJ, Peano S, Saa P, Limido L, Carbonatto M, Ironside J, Torres JM, Pocchiari M, Tagliavini F. Pre-symptomatic detection of prions by cyclic amplification of protein misfolding. *FEBS Lett* 2005; 579: 638-42.
163. Ward HJT, Ironside JW. Controlling the spread of CJD. *Public Service Review: Health* 2005; 4: 6-8.
164. Ward HJT, Ironside JW. Reducing the risk. *Public Service Review: Devolved Government* 2005; 10: 68-9.
165. Ward H. The case control study of risk factors for Creutzfeldt-Jakob disease in the UK. *CJD Support Network Newsletter*, March 2005.
166. Will RG. Creutzfeldt-Jakob disease and blood transfusion. In: Ragaini R, editor. *International Seminar on Nuclear War and Planetary Emergencies 32nd Session*. Singapore: World Scientific Publishing Co. Pte. Ltd, 2005: 115-139.
167. Will RG. Commentary: The risk of variant Creutzfeldt-Jakob disease: reassurance and uncertainty. *Int J Epidemiol* 2005;1-2.
168. Will RG. Creutzfeldt-Jakob disease (CJD). *JNNP* 76(4), 599. 2005.

2004

169. Bishop MT, Ironside JW. Genetic susceptibility to prion diseases. In: Bellamy R, editor. *Susceptibility to Infectious Diseases: The Importance of Host Genetics*. Cambridge: Cambridge University Press, 2004: 361-392.
170. DeArmond SJ, Ironside JW, Bouzamondo-Bernstein E, Peretz D, Fraser JR. Neuropathology of prion diseases. In: Prusiner SB, editor. *Prion Biology and Diseases*. New York: Cold Spring Harbour Laboratory Press, 2004: 777-856.
171. DeArmond SJ, Ironside JW, Bouzamondo-Bernstein E, Peretz D. Neuropathology of Prion Diseases. In: Prusiner SB, editor. *Prion Biology and Diseases*. New York: Cold Spring Harbour, 2004: 777-856.
172. Devereux G, Stelitano L, Verity CM, Nicoll A, Will RG, Rogers P. Variations in neurodegenerative disease across the UK: findings from the national study of Progressive Intellectual and Neurological Deterioration (PIND). *Arch Dis Child* 2004; 89:8-12.
173. Head MW, Ritchie D, Smith N, McLoughlin V, Nailon W, Samad S, Masson S, Bishop M, McCardle L, Ironside JW. Peripheral tissue involvement in sporadic, iatrogenic, and variant Creutzfeldt-Jakob disease: an immunohistological, quantitative and biochemical study. *Am J Pathol* 2004; 164:143-153.
174. Head MW, Bunn TJR, Bishop MT, McLoughlin V, Lowrie S, McKimmie CS, Williams MC, McCardle L, Mackenzie J, Knight R, Will RG, Ironside JW. Prion protein heterogeneity in sporadic but not variant Creutzfeldt-Jakob disease: UK cases 1991-2002. *Ann Neurol* 2004; 55:851-859.
175. Head MW, Ironside JW. Reply to "Striking PrP^{Sc} heterogeneity in inherited prion diseases with the D178N mutation". *Ann Neurol* 2004; 56: 910-11.
176. Hilton DA, Ghani AC, Conyers L, Edwards P, McCardle L, Ritchie D, Penney M, Hegazy D, Ironside JW. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. *J Pathology* 2004; 203:733-739.
177. Hilton DA, Sutak J, Smith MEF, Penney M, Conyers L, Edwards P, McCardle L, Ritchie D, Head MW, Wiley CA, Ironside JW. Specificity of lymphoreticular accumulation of prion protein for variant Creutzfeldt-Jakob disease. *J Clin Pathol* 2004; 57:300-302.
178. Ironside JW, Head MW. Neuropathology and molecular biology of variant Creutzfeldt-Jakob disease. In: Harris D, editor. *Mad Cow Disease and Related Spongiform Encephalopathies*. Berlin: Springer, 2004: 133-159.
179. Ironside JW. Review: Neuropathology of variant Creutzfeldt-Jakob disease. *Pol J Pathol* 2004; 55(3):45-50.
180. Ironside JW, Head MW. Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products. *Haemophilia* 2004; Suppl 4:64-69.
181. Ironside JW, Head MW. Human prion disease. In: Esiri MM, Lee VM-Y, Trojanowski JQ, editors. *The Neuropathology of Dementia*. Cambridge: Cambridge University Press, 2004: 402-426.

182. Knight R. Prion Diseases. *Vox Sang* 2004; 87(1):S104-S106.
183. Knight R, Brazier M, Collins SJ. Human prion diseases: cause, clinical and diagnostic aspects. In: Rabenau HF, Cinatl J, Doerr HW, editors. *Prions. A challenge for science, medicine and the public health system*. Basel: Karger, 2004: 72-97.
184. Knight RSG, Will RG. Prion Diseases. *JNNP* 2004; 75(1):i36-i42.
185. Lekishvili T, Sassoon J, Thompsett AR, Green A, Ironside JW, Brown DR. BSE and vCJD cause disturbance to uric acid levels. *Experimental Neurol* 2004; 190:233-244.
186. Linsell L, Cousens SN, Smith PG, Knight RSG, Zeidler M, Stewart G, De Silva R, Esmonde TFG, Ward HJT, Will RG. A case-control study of sporadic Creutzfeldt-Jakob disease in the United Kingdom: Analysis of clustering. *Neurology* 2004; 63:2077-2083.
187. Llewelyn CA, Hewitt PA, Knight RSG, Amar K, Cousens S, Mackenzie J, Will RG. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. *Lancet* 2004; 363:417-421.
188. McLennan NF, Brennan PM, McNeill A, Davies I, Fotheringham A, Rennison KA, Ritchie D, Brannan F, Head MW, Ironside JW, Williams A, Bell JE. Prion protein accumulation and neuroprotection in hypoxic brain damage. *Am J Pathol* 2004; 65(1): 227-235.
189. Minor P, Newham J, Jones N, Bergeron C, Gregori L, Asher D, van Engelenburg F, Stroebel T, Vey M, Barnard G, Head M, WHO Working Group on International Reference Materials for the Diagnosis and Study of Transmissible Spongiform Encephalopathies. Standards for the assay of Creutzfeldt-Jakob disease specimens. *J Gen Virol* 2004; 85:1777-1784.
190. Moroncini G, Kanu N, Solfrosi L, Abalos G, Telling GC, Head M, Ironside J, Brookes JP, Burton DR, Williamson RA. Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrP^{Sc}. *Proc Natl Acad Sci* 2004; 101: 10404-10409.
191. Paisley D, Banks S, Selfridge J, McLennan NF, Ritchie AM, McEwan C, Irvine DS, Saunders PTK, Manson JC, Melton DW. Male infertility and DNA damage in doppel knockout and prion protein/doppel knockout mice. *Am J Pathol* 2004; 164: 2279-2288.
192. Paramithiotis E, Pinard M, Lawton T, LaBoissiere S, Leathers VL, Zou WQ, Estey LA, Lamontgne J, Lehto MT, Kondejewski LJ, Francoeur GP, Papadopoulos M, Haghigat A, Spatz SJ, Head M, Will R, Ironside J, O'Rourke K, Tonelli Q, Ledebur HC, Chakrabartty A, Cashman NR. Reply to "Properties of a disease-specific prion probe". *Nature Medicine* 2004; 10:11-12.
193. Peden AH, Ironside JW. Review: Pathology of variant Creutzfeldt-Jakob disease. *Folia Neuropathol* 2004; Suppl A:85-91.

194. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. *Lancet* 2004; 364:527-529.
195. Pocchiari M, Puopolo M, Croes EA, Budka H, Gelpi E, Collins S, Lewis V, Sutcliffe T, Giulivi A, Delasnerie-Laupretre N, Brandel J-P, Alperovitch A, Zerr I, Poser S, Kretzschmar HA, Ladogana A, Rietvald I, Mitrova E, Martinez-Martin P, de Pedro Cuesta J, Glatzel M, Aguzzi A, Cooper S, Mackenzie J, van Duijn CM, Will RG. Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. *Brain* 2004; 127:2348-2359.
196. Ritchie DL, Head MW, Ironside JW. Advances in the detection of prion protein in peripheral tissues of variant Creutzfeldt-Jakob disease patients using paraffin-embedded tissue blotting. *Neuropath Appl Neurobiol* 2004; 30(4): 360-368.
197. S-Juan P, Ward HJT, De Silva R, Knight RSG, Will RG. Ophthalmic surgery and Creutzfeldt-Jakob disease. *Br J Ophthalmol* 2004; 88:446-449.
198. Smith PG, Cousens SN, Huillard d'Aignaux J, Ward HJT, Will RG. The epidemiology of variant Creutzfeldt-Jakob disease. In: Harris D, editor. *Mad Cow Disease and Related Spongiform Encephalopathies*. Berlin: Springer, 2004: 161-191.
199. Summers DM, Collie DA, Zeidler M, Will RG. The pulvinar sign in variant Creutzfeldt-Jakob disease. *Arch Neurol* 2004; 61:446-447.
200. te Water Naude J, Verity CM, Will RG, Devereux G, Stellitano L. Is variant Creutzfeldt-Jakob disease in young children misdiagnosed as Alpers' syndrome? An analysis of a national surveillance study. *JNNP* 2004; 75:910-913.
201. Ward HJT, Cousens SN, Smith-Bathgate B, Leitch M, Everington D, Will RG, Smith PG. Obstacles to conducting epidemiological research in the UK general population. *BMJ* 2004; 329:277-279.
202. Ward HJT, Balen A, Will RG. Creutzfeldt-Jakob disease and urinary gonadotrophins. *Human Reproduction* 2004; 19(5):1236-1237.
203. Will R. Variant Creutzfeldt-Jakob disease. *Folia Neuropathol* 2004; 42/Supp A:77-83.
204. Will RG, Alpers MP, Dormont D, Schonberger LB. Infectious and sporadic prion diseases. In: Prusiner SB, editor. *Prion Biology and Diseases*. New York: Cold Spring Harbor Laboratory Press, 2004: 629-671.
205. Will RG. The World of Prions and Prions in the World. In: Kowalski JB, Morrissey RF, editors. *International Kilmer Conference Proceedings*. Laval, Canada: Polyscience Publications, 2004: 83-92.
206. Will RG, Rosinska M. Variant Creutzfeldt-Jakob disease. *Pol J Pathol* 2004; 55:51-57.

207. Will RG, Ward HJT. Clinical features of variant Creutzfeldt-Jakob disease. In: Harris D, editor. *Mad Cow Disease and Related Spongiform Encephalopathies*. Berlin: Springer, 2004: 121-132.
208. Zeidler M, Green A. Advances in diagnosing Creutzfeldt-Jakob disease with MRI and CSF 14-3-3 protein analysis. *Neurology* 2004; 63:410-411.

2003

209. Andrews NJ, Farrington CP, Ward HJT, Cousens SN, Smith PG, Molesworth AM, Knight RSG, Ironside JW, Will RG. Deaths from variant Creutzfeldt-Jakob disease in the UK. *Lancet* 2003; 361:751-752.
210. Armstrong RA, Cairns NJ, Ironside JW, Lantos PL. Does the neuropathology of human patients with variant Creutzfeldt-Jakob disease reflect the haematogenous spread of the disease? *Neurosci Lett* 2003; 348: 37-40.
211. Armstrong RA, Lantos PL, Ironside JW, Cairns NJ. Differences in the density and spatial distribution of florid and diffuse plaques in variant Creutzfeldt-Jakob disease (vCJD). *Clin Neuropathol* 2003; 22: 209-214.
212. Armstrong RA, Lantos PL, Ironside JW, Cairns NJ. Spatial correlation between the vacuolation, prion protein deposition and surviving neurones in patients with variant Creutzfeldt-Jakob disease (vCJD). *J Neural Transm* 2003; 110: 1303-1311.
213. Barr J, Harris N, Chapman K, Head MW, Fraser J. A proteomics (SELDI) approach to disease markers for TSEs. *International Conference on Transmissible Spongiform Encephalopathies Book of Abstracts*, 49. 2003.
214. Barron R, Jamieson E, Thomson V, Melton D, Will R, Ironside JW, Manson J. The 101 L mutation in murine PrP can alter transmission across three species barriers. In: Fraser JR (ed): *Recent Progress in Transmissible Spongiform Encephalopathies*. *Neuropathol and Appl Neurobiol* 2003; 29(5): 208 (abstract).
215. Bird SM, Will RG. Dedication, yet uncertainty. *Statistical Methods in Medical Research* 2003; 12:175-176.
216. Bishop MT, Will RG, Aitchison L, Baybutt H, Gall E, Hart P, Tuzi N, Manson JC. Novel gene targeted transgenic mice as models for codon 129 disease association in Creutzfeldt-Jakob disease. *Munich Conference* . 2003.
217. Boelle P-Y, Thomas G, Valleron A-J, Cesbron J-Y, Will R. Modelling the epidemic of variant Creutzfeldt-Jakob disease in the UK based on age characteristics: updated, detailed analysis. *Statistical Methods in Medical Research* 2003; 12:221-233.
218. Brandel J-P, Preece M, Brown P, Croes E, Laplanche J-L, Agid Y, Will R, Alperovitch A. Distribution of codon 129 genotype in human growth hormone-treated CJD patients in France and the UK. *Lancet* 2003; 362:128-130.

219. Brown P, Bradley R, Detwiler L, Dormont D, Hunter N, Wells GAH, Wilesmith J, Will R, Williams E. Transmissible spongiform encephalopathy as a zoonotic disease. Brussels: 2003.
220. Budka H, Head MW, Ironside JW, Gambetti P, Parchi P, Zeidler M, Tagliavini F. Sporadic Creutzfeldt-Jakob disease. In: Dickson DW, editor. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Basel: ISN Neuropath Press, 2003: 287-297.
221. Collie DA, Summers DM, Sellar RJ, Ironside JW, Cooper S, Zeidler M, Knight R, Will RG. Diagnosing variant Creutzfeldt-Jakob disease with the pulvinar sign: MR imaging findings in 86 neuropathologically confirmed cases. *Am J Neuroradiol* 2003; 24:1560-1569.
222. Cousens S, Everington D, Ward HJT, Huillard J, Will RG, Smith PG. The geographical distribution of variant Creutzfeldt-Jakob disease in the UK: what can we learn from it? *Statistical Methods in Medical Research* 2003; 12:235-246.
223. Cousens SN, Ward HJT, Everington D, Will RG, Smith PG. The geographical distribution of vCJD in Great Britain. In: Fraser JR (ed): *Recent Progress in Transmissible Spongiform Encephalopathies*. *Neuropathol and Appl Neurobiol* 2003; 29(5), 208. (abstract).
224. Everington D, Ward HJT, Cousens SN, Will RG. Population density and variant Creutzfeldt-Jakob disease (CJD). *International Conference on Transmissible Spongiform Encephalopathies Book of Abstracts*, 61. 2003.
225. Fagge TF, Barclay GR. Analysis of PrP expression in blood of CJD patients by DEFLIA and flow cytometry. *Munich Conference, 2003* (abstract).
226. Fraser E, McDonagh AM, Head M, Bishop M, Ironside JW, Mann DMA. Neuronal and astrocytic responses involving the serotonergic system in human spongiform encephalopathies. *Neuropathol and Appl Neurobiol* 2003; 29:482-495.
227. Green AJE, Sivtseva TM, Al'bina PD, Osakovsky VL, Vladimirtsev VA, Zeidler M, Knight RS, Plaonov FA, Shatunov A, Alekseev VP, Krivosshapkin VG, Masters CL, Gajdusek DC, Goldfarb LG. Vilnius encephalomyelitis: intrathecal synthesis of oligoclonal IgG. *J Neuro Sciences* 2003; 212:69-73.
228. Green AJE, Knight RSG, Ironside JW. Cerebrospinal fluid Tau protein as a diagnostic test for variant Creutzfeldt-Jakob disease. *International Conference on Transmissible Spongiform Encephalopathies Book of Abstracts*, 45. 2003.
229. Head MW, Ritchie D, McLoughlin V, Ironside JW. Investigation of PrP^{res} in dental tissues in variant CJD. *British Dental Journal* 2003; 195(6):339-343.
230. Head MW, Bunn TJR, Bishop M, Knight R, Will R, Ironside JW. Heterogeneity in the abnormal prion protein isoforms in the brains of sporadic but not variant Creutzfeldt-Jakob disease patients. *Conference*. 2003.
231. Head MW, Northcott V, Rennison K, Ritchie D, McCardle L, Bunn TJR, McLennan NF, Ironside JW, Tullo AB, Bonshek RE. Prion protein accumulation

- in eyes of patients with sporadic and variant Creutzfeldt-Jakob disease. *Investigative Ophthalmology & Visual Science* 2003; 44(1):342-346.
232. Hill AF, Joiner S, Wadsworth JDF, Sidle KCL, Bell JE, Budka H, Ironside JW, Collinge J. Molecular classification of sporadic Creutzfeldt-Jakob disease. *Brain* 2003; 126:1333-1346.
233. Hilton DA, Ironside JW. Screening for variant Creutzfeldt-Jakob disease. *JNNP* 2003; 74(6):828-829.
234. Ironside JW. The spectrum of safety: variant Creutzfeldt-Jakob disease in the United Kingdom. *Semin Hematol* 2003; 40 (Suppl 3): 16-22.
235. Ironside JW. Variant Creutzfeldt-Jakob disease. *Vet Res Comm* 2003; 27 (Suppl 1): 11-13.
236. Ironside JW, Head MW. Variant Creutzfeldt-Jakob disease and its transmission by blood. *J Thromb Haemost* 2003; 1:1479-1486.
237. Ironside JW, Head MW, Will RG. Variant Creutzfeldt-Jakob disease. In: Dickson DW, editor. *Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders*. Basel: ISN Neuropath Press, 2003: 310-317.
238. Ironside JW. What is to be gained from the study of human transmissible spongiform encephalopathies? In: Fraser JR (ed): *Recent Progress in Transmissible Spongiform Encephalopathies*. *Neuropath and Appl Neurobiol* 2003; 29(5): 207 (abstract).
239. Kapur N, Abbott P, Lowman A, Will RG. The neuropsychological profile associated with variant Creutzfeldt-Jakob disease. *Brain* 2003; 126(12):2693-2702.
240. Knight R. Variant CJD: the present position and future possibilities. *Int J Pediatric Otorhinolaryngology* 2003; 67S1:S81-S84.
241. Knight R, Will B. Prion Diseases. In: Caplan LR, Dichgans J, Diener HC, Kennard C, editors. *Neurological Disorders: Course and Treatment*. USA: Academic Press, 2003: 707-720.
242. Korth C, Kaneko K, Groth D, Heye N, Telling G, Mastrianni J, Parchi P, Gambetti P, Will R, Ironside J, Tremblay P, DeArmond SJ, Prusiner SB. Abbreviated incubation times for human prions in mice expressing a chimeric mouse-human prion protein transgene. *PNAS* 2003; 100 (8):4784-4789.
243. Kovacs GG, Koperek O, Ritchie D, Ironside JW, Wick G, Budka H. Do mobile cells contribute to prion transport? In: Fraser JR (ed): *Recent Progress in Transmissible Spongiform Encephalopathies*. *Neuropathol and Appl Neurobiol* 2003; 29(5): 207 (abstract).
244. Lim R, Dhillon B, Kurian KM, Aspinall PA, Fernie K, Ironside JW. Retention of corneal epithelial cells following Goldmann tonometry: implications for CJD risk. *Br J Ophthalmol* 2003; 87:583-586.

245. Manson J, Barron RM, Baybutt H, Tuzi NL, Jamieson E, Gall E, Aitchison L, Thomson V, McConnell I, Moore R, Melton DW, Ironside J, Will R. Targeting the PrP gene. International Conference on Transmissible Spongiform Encephalopathies Book of Abstracts, 52. 2003.
246. McCormack J, Baybutt H, Everington D, Will R, Ironside J, Manson J. Polymorphism in the regulatory regions of the PRNP gene associated with susceptibility to CJD. International Conference on Transmissible Spongiform Encephalopathies Book of Abstracts, 51. 2003.
247. Nurmi MH, Bishop M, Strain L, Brett F, McGuigan C, Hutchison M, Farrell M, Tilvis R, Erkkila S, Simell O, Knight R, Haltia M. The normal population distribution of PRNP codon 129 polymorphism. *Acta Neurol Scand* 2003; 108:374-378.
248. Paramithiotis E, Pinard M, Lawton T, LaBoissiere S, Leathers VL, Wen-Quan Z, Estey LA, Lamontgne J, Lehto MT, Kondejewski LJ, Francoeur GP, Papadopoulous M, Haghghat A, Spatz SJ, Head M, Will R, Ironside J, O'Rourke K, Tonelli Q, Ledebur HC, Chakrabartty A, Cashman NR. A prion protein epitope selective for the pathologically misfolded conformation. *Nature Medicine* 2003.
249. Pepys MB, Bybee A, Booth DR, Bishop MT, Will RG, Little AM, Prokupek B, Madrigal JA. MHC typing in variant Creutzfeldt-Jakob disease. *Lancet* 2003; 361:487-489.
250. Petzold A, Jenkins R, Watt HC, Green AJE, Thompson EJ, Keir G, Fox NC, Rossor MN. Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease. *Neurosciences Letters* 2003; 2003:167-170.
251. Petzold A, Keir G, Green AJE, Giovanonni G, Thompson EJ. A specific ELISA for measuring neurofilament heavy chain phosphoforms. *J Immunol Methods* 2003; 278(102): 179-190.
252. Richard M, Biacabe A-G, Streichenberger N, Ironside JW, Mohr M, Kopp N, Perret-Liaudet A. Immunohistochemical localization of 14.3.3. zeta protein in amyloid plaques in human spongiform encephalopathies. *Acta Neuropathologica* 2003; 105(3):296-302.
253. Ritchie D, Ironside J. Advances in the immunodetection of prion protein in peripheral tissues of variant CJD. International Conference on Transmissible Spongiform Encephalopathies Book of Abstracts, 45. 2003.
254. Satoh K, Muramoto T, Tanaka T, Kitamoto N, Ironside JW, Nagashima K, Yamada M, Sato T, Mohri S, Kitamoto T. Association of an 11-12 kDa protease-resistant prion protein fragment with subtypes of dura graft-associated Creutzfeldt-Jakob disease and other prion diseases. *J Gen Virol* 2003; 84: 2885-2993.
255. Smith AJ, Bagg J, Ironside JW, Will RG, Scully C. Prions and oral cavity. *J Dent Res* 2003; 82(10):769-775.

256. Taguchi Y, Mohri S, Ironside JW, Muramoto T, Kitamoto T. Humanized knock-in mice expressing chimeric prion protein showed varied susceptibility to different human prions. *Am J Pathol* 2003; 163: 2585-2593.
257. Ward H, Cousens S, Everington D, Lowman A, Smith-Bathgate B, Leitch M, Cooper S, Knight R, Smith P, Will R. Vaccines and Creutzfeldt-Jakob disease (CJD). International Conference on Transmissible Spongiform Encephalopathies Book of Abstracts, 57. 2003.
258. Ward HJ, Head MW, Will RG, Ironside JW. Variant Creutzfeldt-Jakob disease. *Clin Lab Med* 2003; 23(1):87-108.
259. Weller B, Knight R, Will R. An overview of the care issues for Creutzfeldt-Jakob disease. *European J Palliative Care* 2003; 10(1):5-8.
260. Will RG, Knight RSG, Spencer MD. Neuropsychiatric aspects of variant Creutzfeldt-Jakob disease. In: Ragaini R, editor. International Seminar on Nuclear War and Planetary Emergencies - 27th Session - 2002. Singapore: World Scientific Publishing Co. Pte. Ltd., 2003: 674-682.
261. Will RG. Acquired prion disease: iatrogenic CJD, variant CJD, kuru. *British Medical Bulletin* 2003; 66:255-265.
262. Will RG. Variant Creutzfeldt-Jakob disease and bovine spongiform encephalopathy: current status. In: Ragaini R, editor. International Seminar on Nuclear War and Planetary Emergencies - 27th Session - 2002. Singapore: World Scientific Publishing Co Pte Ltd, 2003: 668-673.
263. Will RG. Human prion diseases. In: Warrell DA, Cox TM, Firth JD, Benz EJJ, editors. *Oxford Textbook of Medicine*. Oxford: Oxford University Press, 2003: 1046-1053.
264. Will RG. The biology and epidemiology of variant Creutzfeldt-Jakob disease. *Bulletin et Memoires de l'Academie Royale de Medicine de Belgique* 2003; 158:250-257.
265. Will RG. Progress with prions. *Transfusion Medicine* 2002; 13(1), 2.
266. Will RG. Variant CJD – what are the risks? In: Fraser JR (ed): *Recent Progress in Transmissible Spongiform Encephalopathies*. *Neuropath and Appl Neurobiol* 2003; 29(5): 208 (abstract).

2002

267. Alperovitch A, Will RG. Predicting the size of the vCJD epidemic in France. *CR Biologies* 2002; 325:33-36.
268. Armstrong RA, Cairns NJ, Ironside JW, Lantos P. Laminar distribution of the pathological changes in the cerebral cortex in variant Creutzfeldt-Jakob disease (vCJD). *Folia Neuropathol* 2002; 40(4):165-171.
269. Armstrong RA, Cairns NJ, Ironside JW, Lantos PL. Quantification of vacuolation ("spongiform change"), surviving neurone and prion protein

- deposition in eleven cases of variant Creutzfeldt-Jakob disease. *Neuropathol Appl Neurobiol* 2002; 28(2):129-135.
270. Armstrong RA, Cairns NJ, Ironside JW, Lantos PL. Quantitative variations in the pathology of 11 cases of variant Creutzfeldt-Jakob disease (vCJD). *Pathophysiology* 2002; 8(4):235-241.
271. Armstrong RA, Cairns NJ, Ironside JW, Lantos PL. The spatial patterns of prion protein deposits in cases of variant Creutzfeldt-Jakob disease. *Acta Neuropathol (Berl)* 2002; 104(6):665-669.
272. Barnett F. Nursing patients with variant Creutzfeldt-Jakob disease at home. *Br J Comm Nursing* 2002; 7(9): 445-50.
273. Bramble MG, Ironside JW. Creutzfeldt-Jakob disease: implications for gastroenterology. *Gut* 2002; 50(6):888-890.
274. Choe LH, Green A, Knight RSG, Thompson EJ, Lee KH. Apolipoprotein E and other cerebrospinal fluid proteins differentiate ante mortem variant Creutzfeldt-Jakob disease from ante mortem sporadic Creutzfeldt-Jakob disease. *Electrophoresis* 2002; 23:2242-2246.
275. Connolly JG, Tate RJ, McLennan NF, Brown D, Telling GC, Fraser J, Head MW. Properties of the cellular prion protein expressed in *Xenopus* oocytes. *Neuroreport* 2002; 13(9):1229-1233.
276. Esiri MM, Carter J, Ironside JW. Macrophage and microglial cell immunoreactivity for PrP(c) in a random post-mortem population. *Neuropathol and Appl Neurobiol* 2002; 28(1):79-82.
277. Forloni G, Iussich S, Awan T, Colombo L, Angeretti N, Girola L, Bertani I, Poli G, Caramelli M, Grazia Bruzzone M, Farina L, Limido L, Rossi G, Giaccone G, Ironside JW, Bugiani O, Salmona M, Tagliavini F. Tetracyclines affect prion infectivity. *Proc Natl Acad Sci USA* 2002; 99(16):10849-10854.
278. Green AJE, Ramljak S, Muller WEG, Knight RSG, Schroder HC. 14-3-3 in the cerebrospinal fluid of patients with variant and sporadic Creutzfeldt-Jakob disease measured using a highly sensitive 14-3-3 protein capture assay. *Neurosci Lett* 2002; 324:57-60.
279. Green AJE, Ramljak S, Muller WEG, Knight RSG, Schroder HC. 14-3-3 in the cerebrospinal fluid of patients with variant and sporadic Creutzfeldt-Jakob disease measured using capture assay able to detect low levels of 14-3-3 protein. *Neurosci Lett* 2002; 324:57-60.
280. Green AJE. Cerebrospinal fluid brain-derived proteins in the diagnosis of Alzheimer's disease and Creutzfeldt-Jakob disease. *Neuropathol Appl Neurobiol* 2002; 28:427-440.
281. Green AJE. Biochemical investigations in patients with dementia. *Annals of Clinical Biochemistry* 2002; 39(3):211-220.

282. Green AJE. Use of 14-3-3 in the diagnosis of Creutzfeldt-Jakob disease. *Biochemical Society Transactions* 2002; 30 (4):382-386.
283. Head MW, Northcott V, Rennison K, Ritchie D, McCardle L, Bunn TJR, McLennan NF, Ironside JW, Tullo AB, Bonshek RE. Prion protein accumulation in eyes of patients with sporadic and variant Creutzfeldt-Jakob disease. *Investigative Ophthalmology & Visual Science* 2002; 44(1):342-346.
284. Henry C, Lowman A, Will RG. Creutzfeldt-Jakob disease in elderly people. *Age and Ageing* 2002; 31:7-10.
285. Henry C, Knight R. Clinical features of variant Creutzfeldt-Jakob disease. *Rev Med Virol* 2002; 12:143-150.
286. Hewitt P, Llewelyn C, Will R. Follow up of donations from patients with vCJD. *Vox Sanguinis* 83, 1. 2002.
287. Hilton DA, Ghani AC, Conyers L, Edwards P, McCardle L, Penney M, Ritchie D, Ironside JW. Accumulation of prion protein in tonsil and appendix: review of tissue samples. *BMJ* 2002; 325:633-634.
288. Ironside J, Lowman A. The diagnosis of variant Creutzfeldt-Jakob disease. *Advances in Clinical Neuroscience & Rehabilitation* 2002; 1:6-8.
289. Ironside JW, McCardle L, Horsburgh A, Lim Z, Head MW. Pathological diagnosis of variant Creutzfeldt-Jakob disease. *APMIS* 2002; 110(1):79-87.
290. Ironside JW, Head MW, McCardle L, Knight R. Neuropathology of variant Creutzfeldt-Jakob disease. *Acta Neurobiol Exp* 2002; 62:175-182.
291. Ironside JW. Neuropathology of variant Creutzfeldt-Jakob disease. *C R Acad Sci III* 2002; 325(1):27-31.
292. Kitamoto T, Mohri S, Ironside JW, Miyoshi I, Tanaka T, Kitamoto N, Itohara S, Kasai N, Katsuki M, Higuchi J, Muramoto T, Shin RW. Follicular dendritic cell of the knock-in mouse provides a new bioassay for human prions. *Biochem Biophys Res Commun* 2002; 294(2):280-286.
293. Knight R. CJD: the promise of treatment. *The British Journal of Infection Control* 2002; 3:4.
294. Knight R. Epidemiology of variant CJD. In: Brown F, Seitz R, editors. *Advances in Transfusion Safety*. Basel: Karger, 2002: 87-92.
295. Knight R. CJD: are there distinct neuropsychological features? *JNNP* 2002; 73:612-613.
296. Koperek O, Kovacs GG, Ritchie D, Ironside JW, Budka H, Wick G. Disease-associated prion protein in vessel walls. *American Journal of Pathology* 2002; 161(6):1979-1984.

297. Kovacs GG, Head MW, Hegyi I, Bunn T, Flicker H, Hainfellner JA, McCardle L, Laszlo L, Jarius K, Ironside JW, Budka H. Immunohistochemistry for the prion protein: comparison of different monoclonal antibodies in human prion disease subtypes. *Brain Pathology* 2002; 12(1):1-11.
298. Kovacs GG, Trabattoni G, Hainfellner JA, Ironside JW, Knight RSG, Budka H. Mutations of the prion protein gene: phenotypic spectrum. *J Neurol* 2002; 249:1567-1582.
299. Macleod MA, Stewart G, Zeidler M, Will RG, Knight R. Sensory features of variant Creutzfeldt-Jakob disease. *J Neurol* 2002; 249:706-711.
300. McCormack JE, Baybutt HN, Everington D, Will RG, Ironside JW, Manson JC. PRNP contains both intronic and upstream regulatory regions that may influence susceptibility to Creutzfeldt-Jakob disease. *Gene* 2002; 288:139-146.
301. Minghetti L, Cardone F, Greco A, Puopolo M, Levi G, Green AJE, Knight R, Pocchiari M. Increased CSF levels of prostaglandin E2 in variant Creutzfeldt-Jakob disease. *Neurology* 2002; 58:127-129.
302. Molesworth A, Cousens S, Ward H (reporters). Rising incidence of Creutzfeldt-Jakob disease in Switzerland. *Eurosurveillance Weekly* 2002; 29: 02078.
303. Molesworth A, Horby P, Ward H (reporters). Variant Creutzfeldt-Jakob disease in a Canadian resident. *Eurosurveillance Weekly* 2002; 33: 020815.
304. Molesworth A, Pritchard L, Ward H (reporters). Low incidence of Creutzfeldt-Jakob disease in Europe. *Eurosurveillance Weekly* 2002; 44: 021031.
305. Myles S, Douglas MJ, Ward HJT, Campbell H, Will RG. Variant Creutzfeldt-Jakob disease: costs borne by families. *Health and Social Care in the Community* 2002; 10(2):91-98.
306. Sasaki K, Doh-ura K, Ironside JW, Iwaki T. Increased clusterin (apolipoprotein J) expression in human and mouse brains infected with transmissible spongiform encephalopathies. *Acta Neuropathol (Berl)* 2002; 103(3):199-208.
307. Sellars RJ, Collie DA, Will RG. Progress in understanding Creutzfeldt-Jakob disease. *Am J Neuroradiol* 2002; 23:1070-1072.
308. Spencer MD, Knight RSG, Will RG. First hundred cases of variant Creutzfeldt-Jakob disease: retrospective case note review of early psychiatric and neurological features. *BMJ* 2002; 324:1479-1482.
309. Summers DM, Collie DA, Sellar RJ, Zeidler M, Knight R, Will RG, Ironside JW. The pulvinar sign and diagnosis of Creutzfeldt-Jakob disease. *Neurology* 2002; 59(6):962.
310. van Everbroeck B, Green AJE, Vanmechelen E, Vanderstichele H, Pals P, Sanchez-Guerra M, Cuadrado Corrales N, Martin J-J, Cras P. Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt-Jakob disease. *JNNP* 2002; 73:79-82.

311. Ward HJT, Everington D, Croes EA, Alperovitch A, Delasnerie-Laupretre N, Zerr I, Poser S, van Duijn CM. Sporadic Creutzfeldt-Jakob disease and surgery: A case-control study using community controls. *Neurology* 2002; 59:543-548.
312. Weller B, Ironside JW. Creutzfeldt-Jakob disease and the eye. *Ophthalmic Nursing* 2002; 6(1):12-16.
313. Wiersma S, Cooper S, Knight R, Kennedy AM, Joiner S, Belay S, Schonberger L. Probable variant Creutzfeldt-Jakob disease in a US resident - Florida 2002. *MMWR* 2002; 51:927-929.
314. Will R. Epidemiology of variant Creutzfeldt-Jakob disease. Proceedings - Joint WHO/FAO/OIE Technical Consultation on BSE, public health, animal health and trade 2002;25.
315. Will RG, Knight RSG, Ward HJT, Ironside JW. New variant Creutzfeldt-Jakob disease: the critique that never was. *BMJ* 2002; 325:102.
316. Will RG. Variant Creutzfeldt-Jakob disease. *Acta Neurobiol Exp* 2002; 62:167-173.
317. Will RG. Clinical features of human prion diseases. In: Asbury AK, McKhann GM, McDonald WI, Goadsby PJ, McArthur JC, editors. *Diseases of the Nervous System*. Cambridge: Cambridge University Press, 2002: 1716-1727.
318. Will RG. Variant Creutzfeldt-Jakob disease: How new is new? *JNNP* 2002; 72:285-286.
319. Will RG. Variant Creutzfeldt-Jakob disease. *JNNP* 2002; 72:824.
320. Will RG. The BSE epidemic and susceptibility to variant Creutzfeldt-Jakob disease. *WEON* 2002;19.

2001

321. Al-Shani R, Will RG, Warlow CP. Amount of research interest in rare and common neurological conditions: bibliometric study. *BMJ* 2001; 323: 1461-1462.
322. Barron RM, Thomson V, Jamieson E, Melton DW, Ironside J, Will R, Manson JC. Changing a single amino acid in the N-terminus of murine PrP alters TSE incubation time across three species barriers. *Embo* 2001; 20(18):5070-5078.
323. Brown P, Will RG, Bradley R, Asher DM, Detwiler L. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concerns. *Emerging Infectious Diseases* 2001; 7(1):6-16.
324. Bruce ME, Will RG, Ironside JW, Fraser H. Der Zusammenhang zwischen der neuen CJD-Variante und der BSE. *Prionen und Prionkrankheiten* 2001;435-439.
325. Bruce ME, McConnell I, Will RG, Ironside JW. Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues. *Lancet* 2001; 358:208-209.

326. Collie DA, Sellar RJ, Zeidler M, Colchester AFC, Knight R, Will RG. MRI of Creutzfeldt-Jakob disease: imaging features and recommended MRI protocol. *Clinical Radiology* 2001; 56:726-739.
327. Cousens S, Smith PG, Ward H, Everington D, Knight RSG, Zeidler M, Stewart G, Smith-Bathgate EAB, Macleod MA, Mackenzie J, Will RG. Geographical distribution of variant Creutzfeldt-Jakob disease in Great Britain, 1994-2000. *Lancet* 2001; 357:1002-1007.
328. Garofalo O, McFarlane EH, Iyegbe C, Whatley SA, Campbell IC, Kopp N, Will RG. Variant Creutzfeldt-Jakob disease is not associated with individual abilities to metabolise organophosphates. *JNNP* 2001; 71:558-569.
329. Gill DS, Tredwin CJ, Gill SK, Ironside JW. The transmissible spongiform encephalopathies (prion diseases): a review for dental surgeons. *Int D J* 2001; 51(6): 439-446.
330. Green AJE, Thompson EJ, Stewart GE, Zeidler M, Mackenzie JM, Macleod MA, Ironside JW, Will RG, Knight RSG. Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease. *JNNP* 2001; 70(6):744-748.
331. Green AJE, Knight RSG, Macleod MA, Lowman A, Will RG. Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt-Jakob disease. *Neurology* 2001; 56:986.
332. Head MW, Farquhar CF, Mabbott NA, Fraser JR. The transmissible spongiform encephalopathies: pathogenic mechanisms and strategies for therapeutic intervention. *Expert Opin Ther Targets* 2001; 5(5):569-585.
333. Head MW, Tissingh G, Uitdehaag BMJ, Barkhof F, Bunn TJR, Ironside JW, Kamphorst W, Scheltens P. Sporadic Creutzfeldt-Jakob disease in a young Dutch valine homozygote: atypical molecular phenotype. *Ann Neurol* 2001; 50: 258-261.
334. Head MW. Molecular aspects of variant Creutzfeldt-Jakob disease. *Dementia* 2001; 1: 2-7.
335. Hillier CEM, Llewelyn JG, Neal JW, Ironside JW. Creutzfeldt-Jakob disease in a young person with valine homozygosity at codon129: sporadic or variant? *JNNP* 2001; 70:134-135.
336. Ironside JW, Seilhean D, Head MW, Hauw J-J. Investigation of prion diseases. *Current Topics in Pathology* 2001; 95: 179-205.
337. Ironside JW. From BSE to Creutzfeldt-Jakob (in French). *Biofutur* 2001; April 2001: 6-11.
338. Jamieson E, Jeffrey M, Ironside JW, Fraser JR. Activation of Fas and caspase 3 precedes PrP accumulation in 87V scrapie. *Neurochemistry* 2001; 12: 3567-3572.

339. Jamieson E, Jeffrey M, Ironside JW, Fraser JR. Apoptosis and dendritic dysfunction precede prion protein accumulation in 87V scrapie. *Clin Neurosci and Neuropathol* 2001; 12: 2147-2153.
340. Kapur N, Ironside J, Abbott P, Warner G, Turner A. A neuropsychological-neuropathological case study of variant Creutzfeldt-Jakob disease. *Neurocase* 2001; 7: 261-267.
341. Knight R, Collins S. Human prion diseases: cause, clinical and diagnostic aspects. In: Rabenau HF, Cinatl J, Doerr HW, editors. *Prions. A challenge for science, medicine and public health system*. Basel: Karger, 2001: 68-92.
342. Knight R. Creutzfeldt-Jakob disease: a protein disease. *Proteomics* 2001; 1:763-766.
343. Lasmezas CI, Fournier J-G, Nouvel V, Boe H, Marce D, Lamoury F, Kopp N, Hauw J-J, Ironside J, Bruce M, Dormont D, Deslys J-P. Adaptation of the bovine spongiform encephalopathy agent to primates and comparison with Creutzfeldt-Jakob disease: implications for human health. *PNAS* 2001; 98:4142-4147.
344. Lorains JW, Henry C, Agbumu DA, Rossi M, Bishop M, Will RG, Ironside JW. Variant Creutzfeldt-Jakob disease in an elderly patient. *Lancet* 2001; 357:1339-1340.
345. Lowman A, Knight R, Ironside J. Variant Creutzfeldt-Jakob disease. *Practical Neurology* 2001; 1(1):2-13.
346. McLennan NF, Rennison K, Bell JE, Ironside JW. *In situ* hybridisation analysis of PrP mRNA in human CNS tissues. *Neuropathol Appl Neurobiol* 2001; 27: 373-383.
347. Sivakumar R, Barrett JA, Ironside JW, Playfer JR. Creutzfeldt-Jakob disease presenting as recurrent falls in an older person. *Age Ageing* 2001; 30(4): 356-357.
348. Valleron A-J, Boelle P-Y, Will R, Cesbron J-Y. Estimation of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom. *Science* 2001; 294:1726-1728.
349. Ward HJT. Epidemiology of variant CJD – an update. *Cattle Practice BCVA* 2001; 9(4): 239-241.
350. Will RG. Creutzfeldt-Jakob disease and BSE. In: Lock S, Last JM, Dunea G, editors. *The Oxford Illustrated Companion to Medicine*. Oxford: Oxford University Press, 2001: 206-207.
351. Will RG. The facts about vCJD. *The Practitioner* 2001; 245:469.
352. Will RG. Portrait der neuen variante der Creutzfeldt-Jakob-Krankheit (nvCJD). *Prionen und Prionkrankheiten* 2001;152-157.
353. Wong B-S, Green AJE, Li R, Xie Z, Pan T, Liu T, Chen SG, Gambetti P, Sy M-S. Absence of protease-resistant prion protein in the cerebrospinal fluid of Creutzfeldt-Jakob disease. *J Pathology* 2001; 194:9-14.

354. Zeidler M, Collie DA, Macleod MA, Sellar RJ, Knight R. FLAIR MRI in sporadic Creutzfeldt-Jakob disease. *Neurology* 2001; 56:282.

2000

355. Andrews NJ, Farrington CP, Cousens SN, Smith PG, Ward H, Knight RSG, Ironside JW, Will RG. Incidence of variant Creutzfeldt-Jakob disease in the UK. *Lancet* 2000; 356:481-482.
356. Brown P, Preece M, Brandel J-P, Sato T, McShane L, Zerr I, Fletcher A, Will RG, Pocchiari M, Cashman NR, d'Aignaux JH, Cervenakova L, Fradkin J, Schonberger LB, Collins SJ. Iatrogenic Creutzfeldt-Jakob disease at the millennium. *Neurology* 2000; 55:1075-1081.
357. De Silva R, Will RG. Human prion diseases. In: Davis LE, Kennedy PGE, editors. *Infectious Diseases of the Nervous System*. Oxford: Butterworth Heinemann, 2000: 215-230.
358. Esiri MM, Carter J, Ironside JW. Prion protein immunoreactivity in brain samples from an unselected autopsy population: findings in 200 consecutive cases. *Neuropathol Appl Neurobiol* 2000; 26: 273-284.
359. Green AJE, Thompson EJ, Zeidler M, Stewart G, Mackenzie J, Macleod MA, Knight RSG, Will RG. Raised concentrations of brain specific proteins in patients with sporadic and variant CJD. *JNNP* 2000; 69:419.
360. Head MW, Ironside JW. Inhibition of prion-protein conversion: a therapeutic tool? *Trends in Microbiology* 2000; 8: 6-8.
361. Ironside JW. General features of prion diseases. In: Clark CM, Trojanowski JQ, editors. *Neurodegenerative Diseases*. USA: McGraw-Hill, 2000: 329-340.
362. Ironside JW, Head MW, Bell JE, McCardle L, Will RG. Laboratory diagnosis of variant Creutzfeldt-Jakob disease. *Histopathology* 2000; 37:1-9.
363. Ironside JW, Hilton DA, Ghani A, Johnston NJ, Conyers L, McCardle LM, Best D. Retrospective study of prion-protein accumulation in tonsil and appendix tissues. *Lancet* 2000; 355:1693-1694.
364. Ironside JW. Human prion diseases. *Advances in Clinical Neurosciences* 2000; 10: 291-302.
365. Ironside JW. Update on variant Creutzfeldt-Jakob disease. *Amyloid* 2000; 7: 141-144.
366. Knight R, Will RG. Prion-related diseases and the central nervous system. In: Crockard A, Hayward R, Hoff JT, editors. *Neurosurgery: The Scientific Basis of Clinical Practice Volume 2*. Oxford: Blackwell Science, 2000: 807-814.
367. Knight R. Therapeutic possibilities in CJD: patents 1996-1999. *Exp Opin Ther Patents* 2000; 10:49-57.

368. Kovacs GG, Head MW, Bunn T, Laszlo L, Will RG, Ironside JW. Clinicopathological phenotype of codon 129 valine homozygote sporadic Creutzfeldt-Jakob disease. *Neuropathol and Appl Neurobiol* 2000; 26:463-472.
369. Lueck CJ, McIlwaine GG, Zeidler M. Creutzfeldt-Jakob disease and the eye. I. Background and patient management. *Eye* 2000; 14:263-290.
370. Lueck CJ, McIlwaine GG, Zeidler M. Creutzfeldt-Jakob disease and the eye. II. Ophthalmic and neuro-ophthalmic features. *Eye* 2000; 14:291-301.
371. Macleod MA, Knight R, Stewart G, Zeidler M, Will R. Sensory features of variant Creutzfeldt-Jakob disease. *JNNP* 2000; 69:413-414.
372. Majeed A, Lehmann P, Kirby L, Knight R, Coleman M. Extent of misclassification of death from Creutzfeldt-Jakob disease in England 1979-96: retrospective examination of clinical records. *BMJ* 2000; 320:145-147.
373. McCarron MO, Nicoll JAR, Stewart J, Ironside JW, Mann DMA, Love S, Graham DI, Grubb A. Absence of cystatin C mutation in sporadic cerebral amyloid angiopathy-related hemorrhage. *Neurology* 2000; 54(242): 244.
374. Minor PD, Will RG, Salisbury D. Vaccines and variant CJD. *Vaccine* 2000; 19:409-410.
375. Nailon W, Ironside JW. Variant Creutzfeldt-Jakob disease: immunocytochemical studies and image analysis. *Microscopy Research and Technique* 2000; 50: 2-9.
376. Parchi P, Zou W, Wang W, Brown P, Capellari S, Ghetti B, Kopp N, Schulz-Schaeffer WJ, Kretzschmar HA, Head MW, Ironside JW, Gambetti P, Chen SG. Genetic influence on the structural variations of the abnormal prion protein. *PNAS* 2000; 97(18):10168-10172.
377. Shmakov AN, McLennan NF, McBride P, Farquhar CF, Bode J, Rennison KA, Ghosh S. Cellular prion protein is expressed in the human enteric nervous system. *Nature Medicine* 2000; 6(8): 840-41.
378. Soto C, Kacsak RJ, Saborio GP, Aucouturier P, Wisniewski T, Prelli F, Kacsak R, Mendez E, Harris DA, Ironside J, Tagliavini F, Carp RI, Frangione B. Reversion of prion protein conformational changes by synthetic B-sheet breaker peptides. *Lancet* 2000; 355:192-197.
379. Verity C, Nicoll A, Will R, Devereux G. Progressive intellectual and neurological deterioration (PIND) in children. *Arch Dis Child* 2000; 82(1):A41.
380. Verity CM, Nicoll A, Will RG, Devereux G, Stellitano L. Variant Creutzfeldt-Jakob disease in UK children: a national surveillance study. *Lancet* 2000; 356:1224-1227.
381. Ward HJT. Surveillance of variant Creutzfeldt-Jakob disease in the United Kingdom. *Eurosurveillance* 2000; 5:90-94.

382. Will RG, Zeidler M, Stewart GE, Macleod MA, Ironside JW, Cousens SN, Mackenzie J, Estibeiro K, Green AJE, Knight RSG. Diagnosis of new variant Creutzfeldt-Jakob disease. *Ann Neurol* 2000; 47:575-582.
383. Zeidler M, Green AJE, Zerr I. Case 28-1999: Creutzfeldt-Jakob disease. *New Engl J Med* 2000;292.
384. Zeidler M, Sellar RJ, Collie DA, Knight R, Stewart G, Macleod MA, Ironside JW, Cousens S, Colchester AFC, Hadley DM, Will RG. The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. *Lancet* 2000; 355:1412-1418.
385. Zeidler M. 14-3-3 cerebrospinal fluid protein and Creutzfeldt-Jakob disease. *Ann Neurol* 2000; 47:683.
386. Zeidler M, Ironside JW. The new variant of Creutzfeldt-Jakob disease. *Rev Sci Tech Off Int Epiz* 2000; 19:98-120.
387. Zerr I, Brandel J-P, Masullo C, Wientjens D, De Silva R, Zeidler M, Granieri E, Sampaolo S, van Duijn C, Delasnerie-Laupretre N, Will R, Poser S. European surveillance on Creutzfeldt-Jakob disease: a case-control study for medical risk factors. *J Clin Epid* 2000; 53:747-754.
388. Zerr I, Pocchiari M, Collins S, Brandel J-P, de Pedro Cuesta J, Knight RS, Bernheimer H, Cardone F, Delasnerie-Laupretre N, Cuadrado Corrales N, Ladogana A, Bodemer M, Fletcher A, Awan T, Ruiz Bregon A, Budka H, Laplanche J-L, Will RG, Poser S. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. *Neurology* 2000; 55(6):811-815.

1999

389. Alperovitch A, Zerr I, Pocchiari M, Mitrova E, de Pedro Cuesta J, Hegyi I, Collins S, Kretzschmar H, van Duijn C, Will RG. Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease. *Lancet* 1999; 353:1673-1674.
390. Barclay GR, Munks R, Stewart GE, Turner ML, Will RG. Variant Creutzfeldt-Jakob disease is not related to underlying IgA deficiency. *Transfusion Medicine* 1999; 9:383-386.
391. Bruce ME, Will RG, Ironside JW, Fraser H. Comparison of the biological characteristics of BSE and CJD in mice. In: Iqbal K, Swaab DF, Winblad B, Wisniewski HM, editors. *Alzheimer's Disease and Related Disorders*. John Wiley & Sons Ltd., 1999: 553-560.
392. Churchill D, Churchill DJ, Will RG. Organophosphate exposure and variant Creutzfeldt-Jakob disease. *Lancet* 1999; 353:1410.
393. Cousens SN, Linsell L, Smith PG, Chandrakumar M, Wilesmith JW, Knight RSG, Zeidler M, Stewart G, Will RG. Geographical distribution of variant CJD in the UK (excluding Northern Ireland). *Lancet* 1999; 353:18-21.

394. DeArmond SJ, Ironside JW. Neuropathology of prion diseases. In: Prusiner SB, editor. Prion Biology and Diseases. New York: Cold Spring Harbour, 1999: 585-652.
395. Gray F, Chretien F, Adle-Biassette H, Dorandeu A, Ereau T, Delisle M-B, Kopp N, Ironside JW, Vital C. Neuronal apoptosis in Creutzfeldt-Jakob disease. *J Neuropath Exp Neurol* 1999; 58: 321-328.
396. Greene JDW, Hodges JR, Ironside JW, Warlow CP. Progressive aphasia with rapidly progressive dementia in a 49 year old woman. *JNNP* 1999; 66:238-243.
397. Hill AF, Butterworth RJ, Joiner S, Jackson G, Rossor MN, Thomas DJ, Frosh A, Tolley N, Bell JE, Spencer M, King A, Al-Sarraj S, Ironside JW, Lantos PL, Collinge J. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. *Lancet* 1999; 353:183-184.
398. Ironside JW. New variant Creutzfeldt-Jakob disease. In: Lowe DG, Underwood JCE, editors. Recent Advances in Histopathology. Edinburgh: Churchill Livingstone, 1999: 1-22.
399. Ironside JW. nvCJD: exploring the limits of our understanding. *Biologist* 1999; 46: 172-176.
400. Knight R. The relationship between new variant Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. *Vox Sang* 1999; 76:203-208.
401. Macleod MA, Knight R. New variant Creutzfeldt-Jakob disease. *BCVA* 1999; 7:211-214.
402. Macleod MA, Knight R, Stewart G, Zeidler M, Will R. Clinical features of new variant Creutzfeldt-Jakob disease. *Eur J Neurol* 1999; 6:26.
403. Mallucci GR, Campbell TA, Dickinson A, Beck J, Holt M, Plant G, de Pauw KW, Hakin RN, Clarke CE, Howell S, Davies-Jones GAB, Lawden M, Smith CML, Ince P, Ironside JW, Bridges LR, Dean A, Weeks I, Collinge J. Inherited prion disease with an alanine to valine mutation at codon 117 in the prion protein gene. *Brain* 1999; 122: 1823-1837.
404. Manson JC, Jamieson E, Baybutt H, Tuzi NL, Barron R, McConnell I, Somerville R, Ironside J, Will R, Sy M-S, Melton DW, Hope J, Bostock C. A single amino acid alteration (101L) introduced into murine PrP dramatically alters incubation time of transmissible spongiform encephalopathy. *Embo* 1999; 18(23):6855-6864.
405. Nailon WH, Ironside JW. Creutzfeldt-Jakob disease – statistical texture analysis of abnormal prion protein. In: Proceedings of the first joint meeting of the Biomedical Engineering Society (BMES) and the 21st Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBS), Atlanta, Georgia, 13-16 October 1999.
406. Nailon WH, Ironside JW. Quantitative image analysis of thalamic pathology in new variant Creutzfeldt-Jakob disease. In: Proceedings of Medical Image Understanding and Analysis (MIUA'99), Examinations School, Oxford, 19-20 July 1999.

407. Richard M, Biacabe AG, Perret-Liaudet A, McCardle L, Ironside JW, Kopp N. Protection of personnel and environment against Creutzfeldt-Jakob disease in pathology laboratories. *Clin Exp Pathol* 1999; 47: 192-200.
408. Scott MR, Will RG, Ironside J, Nguyen H-OB, Tremblay P, DeArmond SJ, Prusiner SB. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. *PNAS* 1999; 96(26):15137-15142.
409. Shimizu S, Hoshi K, Muramoto T, Homma M, Ironside JW, Kuzuhara S, Sato T, Yamamoto T, Kitamoto T. Creutzfeldt-Jakob disease with florid-type plaques after cadaveric dura mater grafting. *Arch Neurol* 1999; 36: 357-362.
410. Turner ML, Ironside JW. New variant Creutzfeldt-Jakob disease: the risk of transmission by blood transfusion. *Blood Reviews* 1999; 12: 255-268.
411. Will RG, Cousens SN, Farrington CP, Smith PG, Knight RSG, Ironside JW. Deaths from variant Creutzfeldt-Jakob disease. *Lancet* 1999; 353:979.
412. Will RG. The transmission of prions to humans. *Acta Paediatr Suppl* 1999; 433:28-32.
413. Will RG, Ironside JW. Commentary: Oral infection by the bovine spongiform encephalopathy prion. *PNAS* 1999; 96:4738-4739.
414. Will RG. New variant Creutzfeldt-Jakob disease. *Biomed & Pharmacother* 1999; 53:9-13.
415. Will RG. CJD and blood transfusion. *CJD Support Network Newsletter* 1999;8-9.
416. Will RG. Classical CJD is not forgotten. *CJD Support Network Newsletter* 1999;6-7.
417. Will RG, Alpers MP, Dormont D, Schonberger LB, Tateishi J. Infectious and sporadic prion diseases. In: Prusiner SB, editor. *Prion Biology and Diseases*. New York: Cold Spring Harbour Laboratory Press, 1999: 465-507.
418. Will RG. The relationship between BSE and Creutzfeldt-Jakob disease. In: Goebel K, editor. *International Seminar on Nuclear War and Planetary Emergencies 23rd Session*. Singapore: World Scientific Publishing Co. Pte. Ltd, 1999: 38-39.
419. Will RG, Stewart G, Zeidler M, Macleod MA, Knight RSG. Psychiatric features of new variant Creutzfeldt-Jakob disease. *Psychiatric Bulletin* 1999; 23:264-267.
420. Will RG. Prion related disorders. *J Royal College Physicians London* 1999; 33:311-315.
421. Zeidler M, Knight R, Stewart G, Ironside JW, Will RG, Green AJE, Pocchiari M. Diagnosis of Creutzfeldt-Jakob disease. Routine tonsil biopsy for diagnosis of new variant Creutzfeldt-Jakob disease is not justified. *BMJ* 1999; 318:538.

1998

422. Baker HF, Ridley RM, Wells GAH, Ironside JW. Prion protein immunohistochemical staining in the brains of monkeys with transmissible spongiform encephalopathy. *Neuropathol and Appl Neurobiol* 1998; 24:476-486.
423. Chamberland ME, Epstein J, Dodd RY, Persing D, Will RG, DeMaria Jr A, Emmanuel JC, Pierce B, Khabbaz R. Blood safety. *Emerging Infectious Diseases* 1998; 4(3):410-411.
424. Collie DA, Sellar RJ, Ironside J, Zeidler M, Stewart G, Knight R. New variant Creutzfeldt-Jakob disease: diagnostic features on MRI with histopathological correlation. *Proc ASNR* 1998; 20:139.
425. De Silva R, Patterson J, Hadley D, Russell A, Turner M, Zeidler M. Single photon emission computed tomography in the identification of new variant Creutzfeldt-Jakob disease: case reports. *BMJ* 1998; 316:17-18.
426. Dorandeu A, Wingertsman L, Ironside JW, Delisle M-B, Vital C, Parchi P, Montagna P, Lugaresi E, Budka H, Gambetti P, Gray F. Neuronal apoptosis in fatal familial insomnia. *Brain Pathology* 1998; 8: 531-537.
427. Hilton DA, Fathers E, Edwards P, Ironside JW, Zajicek J. Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease. *Lancet* 1998; 352(9129):703-704.
428. Ironside JW. Review article: New variant Creutzfeldt-Jakob disease. *Neuropathology* 1998; 18:131-138.
429. Ironside JW. Neuropathological findings in new variant CJD and experimental transmission of BSE (mini review). *FEMS Immunology & Medical Microbiology* 1998; 21:91-95.
430. Ironside JW. Review article: prion diseases in man. *J Pathology* 1998; 186:227-234.
431. Ironside JW, Knight RSG, Will RG, Smith PG, Cousens SN. New variant Creutzfeldt-Jakob disease is more common in Britain than elsewhere. *BMJ* 1998; 317:352.
432. Ironside JW. The work of the National CJD Surveillance Unit. *ACP News* 1998; 27-29.
433. Ironside JW. Creutzfeldt-Jakob disease – the story so far. *Proc R Coll Phys, Edinburgh* 1998; 28: 143-149.
434. Knight R, Stewart G. The new variant form of Creutzfeldt-Jakob disease. *FEMS Immunology & Medical Microbiology* 1998; 21:97-100.
435. Knight R. The diagnosis of prion diseases. *Parasitology* 1998; 117:S3-S11.
436. Knight R. Creutzfeldt-Jakob disease: clinical features, epidemiology and tests. *Electrophoresis* 1998; 19:1306-1310.

437. Lee CA, Ironside JW, Bell JE, Giangrande P, Ludlam C, Esiri MM, McLaughlin JE. Retrospective neuropathological review of prion disease in UK haemophilic patients. *Thromb Haemost* 1998; 80(6): 909-11.
438. McLean CA, Ironside JW, Alpers MP, Brown PW, Cervenakova L, Anderson RM, Masters CL. Comparative neuropathology of kuru with the new variant of Creutzfeldt-Jakob disease: evidence for strain of agent predominating over genotype host. *Brain Pathology* 1998; 8:429-437.
439. Nailon WH, Ironside JW. Image processing in neuropathology. In: *Proceedings of the Second Workshop on Advances in Brain Morphometry*, Leeds Castle, Kent, 24-26 October 1998.
440. Piccardo P, Dlouhy S, Lievens PMJ, Young K, Bird TD, Nochlin D, Dickson DW, Vinters HV, Zimmerman TR, Mackenzie IRA, Kish SJ, Ang LC, De Carli C, Pocchiari M, Brown P, Gibbs Jr CJ, Gajdusek DC, Bugiani O, Ironside J, Tagliavini F, Ghetti B. Phenotypic variability of Gerstmann-Straussler-Scheinker disease is associated with prion protein heterogeneity. *J Neuropathol and Experimental Neurol* 1998; 57(10):979-988.
441. Schultz DW, Lennox GG, Ironside JW, Warlow CP. Behavioural disturbance and visual hallucinations in a 78 year old man. *JNNP* 1998; 65(6): 933-8.
442. Sidle K, Will B, Lantos P, Collinge J. Transmission studies of fatal familial insomnia. In: Morrison D, editor. *Prions and Brain Diseases in Animals and Humans*. Coppel, Switzerland: Plenum Press, 1998: 299-302.
443. Stewart GE, Ironside JW. New variant Creutzfeldt-Jakob disease. *Current Opinion in Neurology* 1998; 11: 259-262.
444. Turner ML, Ironside JW. New-variant Creutzfeldt-Jakob disease: the risk of transmission by blood transfusion. *Blood Review* 1998; 12:255-268.
445. van Duijn CM, Delasnerie-Laupretre N, Masullo C, Zerr I, De Silva R, Wientjens DPWM, Brandel J-P, Weber T, Bonavita V, Zeidler M, Alperovitch A, Poser S, Granieri E, Hofman A, Will RG. Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95. *Lancet* 1998; 351:1081-1085.
446. Will R. New variant Creutzfeldt-Jakob disease. In: Morrison D, editor. *Prions and Brain Diseases in Animals and Humans*. New York: Plenum Press, 1998: 141-145.
447. Will RG, Kimberlin RH. Creutzfeldt-Jakob disease and the risk from blood or blood products. *Vox Sang* 1998; 75:178-180.
448. Will RG. New variant Creutzfeldt-Jakob disease. In: Brown F, Griffiths E, Horaud F, Petriccioni JC, editors. *Safety of Biological Products prepared from Mammalian Cell Culture*. Basel: Karger, 1998: 79-84.
449. Will RG, Campbell MJ, Moss TH, Bell JE, Ironside JW. FFI cases from the United Kingdom. *Brain Pathology* 1998; 8:562-563.

450. Will RG. Epidemiology of Creutzfeldt-Jakob disease. In: Morrissey RF, Kowalski JB, editors. *Sterilization of Medical Products*. Champlain, N.Y.: Polyscience Publications Inc., 1998: 202-211.
451. Will RG, Alperovitch A, Poser S, Pocchiari M, Hofman A, Mitrova E, De Silva R, D'Alessandro M, Delasnerie-Laupretre N, Zerr I, van Duijn C. Descriptive epidemiology of Creutzfeldt-Jakob disease in six European countries, 1993-1995. *Ann Neurol* 1998; 43:763-767.
452. Will RG. New Variant Creutzfeldt-Jakob Disease. *The Darlington Postgraduate Journal* 1998; 17(1):35-42.
453. Will RG. Update on surveillance of Creutzfeldt-Jakob disease in Europe. In: Office International des Epizooties, editor. *Epidemiological studies and research on transmissible spongiform encephalopathies*. Paris: Office International des Epizooties, 1998: 10-12.
454. Will RG. Transmissible spongiform encephalopathy: BSE/CJD - the new variant CJD. In: Goebel K, editor. *The Science and Culture Series: Nuclear Strategy and Peace Technology*. International Seminar on nuclear war and planetary emergencies. Singapore: World Scientific Publishing Co. Pte. Ltd, 1998: 133-134.
455. Zeidler M, Brown P. More patients should be excluded from being tissue donors. *BMJ* 1998; 316:1170-1171.
456. Zeidler M, Will RG, Ironside JW, Sellar R, Wardlaw J. Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. Magnetic resonance imaging is not a sensitive test for Creutzfeldt-Jakob disease. *BMJ* 1998; 312: 844.

1997

457. Bell JE, Ironside JW. Principles and practice of "high-risk" brain banking. *Neuropath Appl Neurobiol* 1997; 23: 281-288.
458. Bell JE, Gentleman SM, Ironside JW, McCardle L, Lantos PL, Doey L, Lowe J, Fergusson J, Luthert P, McQuaid S. Prion protein immunocytochemistry – UK five centre consensus report. *Neuropath Appl Neurobiol* 1997; 23: 26-35.
459. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A, McCardle L, Chree A, Hope J, Birkett C, Cousens S, Fraser H, Bostock CJ. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. *Nature* 1997; 389:498-501.
460. Collinge J, Hill AF, Sidle KAC, Ironside J. Biochemical typing of scrapie strains (letter). *Nature* 1997; 386:564.
461. Cousens SN, Vynnycky E, Zeidler M, Will RG, Smith PG. Predicting the CJD epidemic in humans. *Nature* 1997; 385:197-198.
462. Cousens SN, Zeidler M, Esmonde TF, De Silva R, Wilesmith JW, Smith PG, Will RG. Sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of epidemiological surveillance data for 1970-96. *BMJ* 1997; 315:389-395.

463. De Silva R, Findlay C, Awad I, Harries-Jones R, Knight R, Will R. Creutzfeldt-Jakob disease in the elderly. *Postgrad Med J* 1997; 73:557-559.
464. Diring H, Beekes M, Ozel M, Simon D, Queck I, Cardone F, Pocchiari M, Ironside JW. Highly infectious purified preparations of disease-specific amyloid of transmissible spongiform encephalopathies are not devoid of nucleic acids of viral size. *Intervirology* 1997; 40:238-246.
465. Hill AF, Will RG, Ironside J, Collinge J. Type of prion protein in UK farmers with Creutzfeldt-Jakob disease. *Lancet* 1997; 350:188.
466. Hill AF, Zeidler M, Ironside J, Collinge J. Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. *Lancet* 1997; 349:99-100.
467. Ironside JW, Bell JE. Pathology of prion diseases. In: Collinge J, Palmer MS (eds) *Prion Diseases*, Oxford University Press, Oxford 1997, pp 25-50.
468. Ironside JW. Transmissible Spongiform Encephalopathies. In: Greenwood D, Slack RCB, Peutherer JF (eds) *Medical Microbiology*, Churchill Livingstone, Edinburgh 1997, 15th edition, pp 548-555.
469. Ironside JW. New variant Creutzfeldt-Jakob disease in the UK: clinical and pathological studies. *Brain Pathology* 1997; 7:1243-1245.
470. Ironside JW. Transmissible spongiform encephalopathies: the relationship between Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. *Current Opinion in Infectious Diseases* 1997; 10: 1-14.
471. Ironside JW, Bell JE. Florid plaques and new variant Creutzfeldt-Jakob disease. *Lancet* 1997; 350:1475.
472. Ironside JW. New variant CJD. In: *Recent Advances in Histopathology*. Lowe D, Underwood JCE (eds), Churchill Livingstone, Edinburgh 1997; 944.
473. Ironside JW. General features of prion diseases. In: *Clinical and Pathological Basis of Neurodegeneration*. Trojanowski JQ (ed), Williams and Wilkins, Baltimore 1997: 943.
474. Ironside JW. The new variant form of Creutzfeldt-Jakob disease: a novel prion protein amyloid disorder. *Amyloid* 1997; 4: 66-69.
475. McCardle L. Human prion diseases (Biomedical Comment). *B J Biomed Sci* 1997; 54: 2-4.
476. McLean CA, Ironside JW, Masters CL. Comparative neuropathology in kuru and new variant CJD. *Brain Pathology* 1997; 7:1247.
477. McNaughton HK, Will RG. Creutzfeldt-Jakob disease presenting acutely as stroke: an analysis of 30 cases. *Neurological Infections and Epidemiology* 1997; 2:19-24.

478. Nicoll JA, Burnett C, Love S, Graham DI, Dewar D, Ironside JW, Stewart J, Vinters HV. High frequency of apolipoprotein E epsilon 2 allele in haemorrhage due to cerebral amyloid angiopathy. *Ann Neurol* 1997; 41: 716-721.
479. Raymond GJ, Hope J, Kocisko DA, Priola SA, Raymond LD, Bossers A, Ironside J, Will RG, Chen SG, Petersen RB, Gambetti P, Rubenstein R, Smits MA, Lansbury PT, Caughey B. Molecular assessment of the potential transmissibilities of BSE and scrapie to humans. *Nature* 1997; 388:285-288.
480. Sellar RJ, Will RG, Zeidler M. MR imaging of new variant Creutzfeldt-Jakob disease: the pulvinar sign. *Neuroradiology* 1997; 39:S53.
481. Sutherland K, De Silva R, Will RG. Clinical diagnosis of Creutzfeldt-Jakob disease using a multi-layer perceptron neural network classifier. *Journal of Intelligent Systems* 1997; 7(1-2):1-18.
482. Whittle IR, Will RG, Ironside JW. Brain biopsy and patients with atypical presentations of sporadic Creutzfeldt-Jakob disease. *JNNP* 1997; 63:547-548.
483. Will RG, Knight RSG, Zeidler M, Stewart G, Ironside JW, Cousens SN, Smith PG. Reporting of suspect new variant Creutzfeldt-Jakob disease. *Lancet* 1997; 349:847.
484. Will RG. A new variant of Creutzfeldt-Jakob disease in the UK. *Society for Veterinary Epidemiology and Preventative Medicine - Proceedings* 1997;1-278.
485. Will RG. New variant Creutzfeldt-Jakob disease. *Alzheimer's Review* 1997; 7(1):145-147.
486. Zeidler M, Stewart GE, Barraclough CR, Bateman DE, Bates D, Burn DJ, Colchester AC, Durward W, Fletcher NA, Hawkins SA, Mackenzie JM, Will RG. New variant Creutzfeldt-Jakob disease: neurological features and diagnostic tests. *Lancet* 1997; 350:903-907.
487. Zeidler M, Johnstone EC, Bamber RWK, Dickens CM, Fisher CJ, Francis AF, Goldbeck R, Higgo R, Johnson-Sabine EC, Lodge GJ, McGarry P, Mitchell S, Tarlo L, Turner M, Ryley P, Will RG. New variant Creutzfeldt-Jakob disease: psychiatric features. *Lancet* 1997; 350:908-910.
488. Zeidler M, Stewart G, Cousens SN, Estibeiro K, Will RG. Codon 129 genotype and new variant CJD. *Lancet* 1997; 350:668.
489. Zeidler M. Advances in the diagnosis of Creutzfeldt-Jakob disease. *Progress in Neurology and Psychiatry* 1997;22-25.
490. Zeidler MD, Estibeiro K, Will RG. The genetics of Creutzfeldt-Jakob disease in the United Kingdom. *JNNP* 1997;206.

1996

491. Baker HF, Ridley RM, Wells GAH, Ironside JW. Spontaneous spongiform encephalopathy in a monkey. *Lancet* 1996; 348:955-956.

492. Budka H, Aguzzi A, Brown P, Brucher J-M, Bugiani O, Collinge J, Diringer H, Gullotta F, Haltia M, Hauw J-J, Ironside JW, Kretzschmar HA, Lantos PL, Masullo C, Pocchiari M, Schlote W, Tateishi J, Will RG. Konsensusbericht: Gewebsbehandlung bei verdacht auf Creutzfeldt-Jakob-Krankheit und andere spongiforme enzephalopathien (prionen-krankheiten) des menschen. *Pathologie* 1996; 17:171-176.
493. Campbell TA, Palmer MS, Will RG, Gibb WRG, Luthert PJ, Collinge J. A prion disease with a novel 96-base pair insertional mutation in the prion protein gene. *Neurology* 1996; 46:761-766.
494. Collinge J, Beck J, Campbell T, Estibeiro K, Will RG. Prion protein gene analysis in new variant cases of Creutzfeldt-Jakob disease. *Lancet* 1996; 348:56.
495. Collinge J, Sidle KCL, Meads J, Ironside J, Hill AF. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. *Nature* 1996; 383:685-690.
496. Hawkins SA, Droogan AG, Esmonde TF, Allen IV, Will RG, Ironside JW. The first Irish case of a newly recognised phenotype of Creutzfeldt-Jakob disease. *Ann Neurol* 1996; 40(3):523-524.
497. Holmes SJ, Ironside JW, Shalet SM. Neurosurgery in a patient with Creutzfeldt-Jakob disease after pituitary derived growth hormone therapy in childhood. *JNNP* 1996; 60:333-335.
498. Ironside JW. Neuropathological diagnosis of human prion disease: morphological studies. In: Baker H, Ridley RM (eds) *Methods in Molecular Medicine: Prion Diseases*. Totowa, NJ: Humana Press Inc, 1996: 35-37.
499. Ironside JW, Sutherland K, Bell JE, McCardle L, Barrie C, Estibeiro K, Zeidler M, Will RG. A new variant of Creutzfeldt-Jakob disease: neuropathological and clinical features. Cold Spring Harbour Laboratory Press 1996;523-530.
500. Ironside JW. Review: Creutzfeldt-Jakob disease. *Brain Pathology* 1996; 6:379-388.
501. Ironside JW, Bell JE. The 'high-risk' neuropathological autopsy in AIDS and Creutzfeldt-Jakob disease: principles and practice. *Neuropathol and Appl Neurobiol* 1996; 22:388-393.
502. Ironside JW, Sutherland K, Bell JE, McCardle L, Barrie C, Estibeiro K, Zeidler M, Will RG. A new variant of Creutzfeldt-Jakob disease: neuropathological and clinical features. *Cold Spring Harbour Symposia on Quantitative Biology* 1996; LXI: 523-530.
503. Ironside JW. Prion diseases: update on Creutzfeldt-Jakob disease. *Neuropath Appl Neurobiol* 1996; 22: 446.
504. Ironside JW, Goodbrand IA, Bell JE, Will RG. PrP accumulation in sporadic and iatrogenic CJD. *Neuropath Appl Neurobiol* 1996; 22: 7.
505. Ironside JW. Human prion diseases. *J Neural Transm* 1996; 47(Suppl): 231-246.

506. Knight R. Creutzfeldt-Jakob disease. In: Katz K, editor. *Developments in Psychiatry, 1982-1994*. London: Mark Allen, 1996: 305-317.
507. Kretzschmar HA, Ironside JW, DeArmond SJ, Tateishi J. Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. *Arch Neurol* 1996; 53:913-920.
508. Lasmezas CI, Deslys J-P, Demaimay R, Adjou KT, Lamoury F, Dormont D, Robain I, Ironside JW, Hauw J-J. BSE transmission to macaques. *Nature* 1996; 381:743-744.
509. Macdonald ST, Sutherland K, Ironside JW. A quantitative and qualitative analysis of prion protein immunohistochemical staining in Creutzfeldt-Jakob disease using four anti prion protein antibodies. *Neurodegeneration* 1996; 5(1): 87-94.
510. Macdonald ST, Sutherland K, Ironside JW. Prion protein genotype and pathological phenotype studies in sporadic Creutzfeldt-Jakob disease. *Neuropathol and Appl Neurobiol* 1996; 22:285-292.
511. Peet R, Sutherland K, Ironside JW. Quantitative methods in the analysis of a new variant of Creutzfeldt-Jakob disease. *Electronic J Path Hist* 1996; 2: 964-967.
512. Roos RAC, Wintzen AR, Will RG, Ironside JW, van Duinen SG. Een patient met de ziekte van Creutzfeldt-Jakob na behandeling met humaan groeihormoon. *Ned Tijdschr Geneesk* 1996; 40(22):1190-1193.
513. Sutherland K, Ironside JW. Quantifying spongiform change in the brain by image analysis. *Microscopy and Analysis* 1996;15-16.
514. Sutherland K, Goodbrand IA, Bell JE, Ironside JW. Objective quantification of prion protein in spinal cords of cases of Creutzfeldt-Jakob disease. *Analytical Cellular Pathology* 1996; 10: 25-35.
515. Sutherland K, Macdonald S, Ironside JW. Quantification and analysis of the neuropathological features of Creutzfeldt-Jakob disease. *J Neurosci Methods* 1996; 64: 123-132.
516. Sutherland K, Ironside JW. Automatic quantification of astrocyte numbers in Creutzfeldt-Jakob disease. *Neuropath Appl Neurobiol* 1996; 22: 7.
517. Sutherland K, Ironside JW. Automatic computerised image analysis of neuropathology in Creutzfeldt-Jakob disease. In: *Transmissible Subacute Spongiform Encephalopathies: Prion Diseases*. Court L, Dodet B (eds): Elsevier, Paris 1996: 89-95.
518. Wientjens DPWM, Delasnerie-Laupretre N, Hofman A, Poser S, Pocchiari M, Will RG. Incidence of Creutzfeldt-Jakob disease in Europe. *Neurology* 1996; 46:A290.
519. Wientjens DPWM, Davanipour Z, Hofman A, Kondo K, Matthews WB, Will RG, van Duijn CM. Risk factors for Creutzfeldt-Jakob disease: a reanalysis of case-control studies. *Neurology* 1996; 46:1287-1291.

520. Will RG. Creutzfeldt-Jakob disease. In: Goebel K, editor. International Seminar of Nuclear War - 21st Session. Singapore: World Scientific Publishing Co. Pte Ltd., 1996: 53.
521. Will RG. Are prions relevant to transfusion? *Transfusion Medicine* 1996; 6(Suppl 2):1.
522. Will RG. Surveillance of Creutzfeldt-Jakob disease. *Science in Parliament* 1996; 53(6):4-5.
523. Will RG. Incidence of Creutzfeldt-Jakob disease in the European Community. In: Gibbs CJ Jr, editor. *Bovine Spongiform Encephalopathy: The BSE Dilemma*. NY: Springer-Verlag, 1996: 364-374.
524. Will RG. Transmissibility of bovine spongiform encephalopathy from animals to humans. In: Court L, Dodet B, editors. *Transmissible Subacute Spongiform Encephalopathies: Prion Diseases*. Paris: Elsevier, 1996: 391-393.
525. Will RG, Zeidler M. Diagnosing Creutzfeldt-Jakob disease. *BMJ* 1996; 313:833-834.
526. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, Poser S, Pocchiari M, Hofman A, Smith PG. A new variant of Creutzfeldt-Jakob disease in the UK. *Lancet* 1996; 347:921-925.
527. Will RG, Ironside JW, Hornlimann B, Zeidler M. Creutzfeldt-Jakob disease. *Lancet* 1996; 347:65-66.
528. Will RG, Zeidler M, Brown P, Harrington MG, Lee KH, Kenney KL. Cerebrospinal fluid test for new variant Creutzfeldt-Jakob disease. *Lancet* 1996; 348:955-956.
529. Will RG. Surveillance of Prion Diseases in Humans. In: Baker H, Ridley RM, editors. *Methods in Molecular Medicine: Prion Diseases*. Totowa, NJ: Humana Press Inc, 1996: 119-137.
530. Windl O, Dempster M, Estibeiro JP, Lathe R, De Silva R, Esmonde T, Will R, Springbett A, Campbell TA, Sidle KCL, Palmer MS, Collinge J. Genetic basis of Creutzfeldt-Jakob disease in the United Kingdom: a systematic analysis of predisposing mutations and allelic variation in the PRNP gene. *Hum Genet* 1996; 98:259-264.
531. Young GR, Fletcher NA, Zeidler M, Estibeiro KL, Ironside JW. Creutzfeldt-Jakob disease in a beef farmer. *Lancet* 1996; 348:610-611.
532. Zeidler M, Will RG, Ironside JW, Sellar R, Wardlaw J. Magnetic resonance imaging is not a sensitive test for Creutzfeldt-Jakob disease. *Lancet* 1996; 312:844.

1995

533. Bateman D, Hilton D, Love S, Zeidler M, Beck J, Collinge J. Sporadic Creutzfeldt-Jakob disease in a 18-year old in the UK. *Lancet* 1995; 346:1155-1156.
534. Brown P, Kenney K, Little B, Ironside J, Will RG, Cervenakova L, Bjork RJ, San Martin RA, Safar J, Roos R, Haltia M, Gibbs CJ Jr, Gajdusek DC. Intracerebral distribution of infectious amyloid protein in spongiform encephalopathy. *Ann Neurol* 1995; 38:245-253.
535. Budka H, Aguzzi A, Brown P, Brucher J-M, Bugiani O, Gullotta F, Haltia M, Hauw J-J, Ironside JW, Jellinger K, Kretzschmar HA, Lantos PL, Masullo C, Scholte W, Tateishi J, Weller RO. Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). *Brain Pathology* 1995; 5(4): 459-466.
536. Budka H, Aguzzi A, Brown P, Brucher J-M, Bugiani O, Collinge J, Diringer H, Gullotta F, Haltia M, Hauw J-J, Ironside JW, Kretzschmar HA, Lantos PL, Masullo C, Pocchiari M, Schlote W, Tateishi J, Will RG. Tissue Handling in Suspected Creutzfeldt-Jakob Disease (CJD) and Other Human Spongiform Encephalopathies (Prion Diseases). *Brain Pathology* 1995; 5:319-322.
537. Collinge J, Palmer MS, Sidle KCL, Gowland I, Medori R, Ironside J, Lantos P. Transmission of fatal familial insomnia to laboratory animals. *Lancet* 1995; 346:569-570.
538. Delasnerie-Laupretre N, Poser S, Pocchiari M, Wientjens DPWM, Will RG. Creutzfeldt-Jakob disease in Europe. *Lancet* 1995; 346:898.
539. Goodbrand IA, Ironside JW, Nicolson D, Bell JE. Prion protein accumulation in the spinal cords of patients with sporadic and growth hormone associated Creutzfeldt-Jakob disease. *Neurosci Lett* 1995; 183:127-130.
540. Goodbrand IA, Nicolson D, Bell JE, Ironside JW. Prion protein localization in the spinal cord and brain stem in iatrogenic and sporadic CJD: an immunocytochemical study with pathogenetic implications. *Neuropath Appl Neurobiol* 1995; 21: 444.
541. Ironside JW, Bell JE. PrP immunocytochemistry in sporadic and iatrogenic CJD. *Clin Neurosci* 1995; 48(Suppl): 43.
542. Jeffrey M, Goodbrand IA, Goodsir CM. Pathology of the transmissible spongiform encephalopathies with special emphasis on ultrastructure. *Micron* 1995; 26(3): 277-298.
543. Nicholl D, Windl O, De Silva R, Sawcer S, Dempster M, Ironside JW, Estibeiro JP, Yuill GM, Lathe R, Will RG. Inherited Creutzfeldt-Jakob disease in a British family associated with a novel 144 base pair insertion of the prion protein gene. *JNNP* 1995; 58:65-69.
544. Pickering-Brown SM, Mann DMA, Owen F, Ironside JW, De Silva R, Roberts DA, Balderson DJ, Cooper PN. Allelic variations in apolipoprotein E and prion

- protein genotype related to plaque formation and age of onset in sporadic Creutzfeldt-Jakob disease. *Neurosciences Letters* 1995; 187:127-129.
545. Revesz T, Daniel SE, Lees AJ, Will RG. A case of progressive subcortical gliosis associated with deposition of abnormal prion protein (PrP). *JNNP* 1995; 58:759-760.
546. Smith PEM, Zeidler M, Ironside JW, Estibeiro P, Moss TH. Creutzfeldt-Jakob disease in a dairy farmer. *Lancet* 1995; 346:898.
547. Sutherland K, Macdonald ST, Barrie C, Ironside JW. Assessment of neuropathological targeting in Creutzfeldt-Jakob disease: a quantitative immunocytochemical study. *Neuropathol and Appl Neurobiol* 1995;15.
548. Will RG. Creutzfeldt-Jakob disease. *Postgraduate Doctor Middle East* 1995; 18(5):177-182.
549. Will RG. Possible Creutzfeldt-Jakob disease in an adolescent. *World Health Organisation Weekly Epidemiological Record* 1995; 15: 105-106.
550. Will RG. Epidemiology of CJD in the UK. *Medien in der Medizin* 1995;11.
551. Will RG. Commentary: Scrapie revisited. *BMJ* 1995; 311:1075-1076.

1994

552. Alperovitch A, Brown P, Weber T, Pocchiari M, Hofman A, Will RG. Incidence of Creutzfeldt-Jakob disease in Europe 1993. *Lancet* 1994; 343:918.
553. Brown P, Kenney K, Little B, Ironside J, Safar J, Rohwer R, Roos R, Wollmann R, Gibbs CJ Jr, Gajdusek DC. Comparison of clinical features, neuropathology and intracerebral distribution of PrP amyloid protein in the brains of patients with spongiform encephalopathy. *Neurobiol Aging* 1994; 15(Suppl 1):S150.
554. Brown P, Cervenakova L, Goldfarb LG, McCombie WR, Rubenstein R, Will RG, Pocchiari M, Martinez-Lage JF, Scalici C, Masullo C, Graupera G, Ligan J, Gajdusek DC. Iatrogenic Creutzfeldt-Jakob disease: an example of the interplay between ancient genes and modern medicine. *Neurology* 1994; 44:291-293.
555. De Silva R, Windl O, Dempster M, Estibeiro P, Esmonde T, Lathe R, Ironside JW, Will RG. Prion protein genotype in Creutzfeldt-Jakob disease: the Edinburgh experience. *Ann Neurol* 1994; 36(2):272.
556. De Silva R, Ironside JW, Barrie C, Esmonde TFG, Bell JE, Will RG. Amyloid plaques in Creutzfeldt-Jakob disease: prevalence and clinical correlates. *Ann Neurol* 1994; 36(2):273.
557. De Silva R, Ironside JW, McCardle L, Esmonde TFG, Bell JE, Will RG. Neuropathological phenotype and "prion protein" genotype correlation in sporadic Creutzfeldt-Jakob disease. *Neurosciences Letters* 1994; 179:50-52.

558. De Silva R, Esmonde TFG. Iatrogenic transmission of Creutzfeldt-Jakob disease: an update. *CNS Drugs* 1994; 2(2): 96-101.
559. Esmonde TFG, Will RG, Ironside J, Cousens S. Creutzfeldt-Jakob disease: a case-control study. *Neurology* 1994; 44 (Suppl 2):A193.
560. Gray F, Chretien F, Cesaro P, Chatelain J, Beaudry P, Laplanche JL, Mikol J, Bell J, Gambetti P, Degos JD. Creutzfeldt-Jakob disease and cerebral amyloid angiopathy. *Acta Neuropathol* 1994; 88: 106-111.
561. Hayward PAR, Bell JE, Ironside JW. Prion protein immunocytochemistry: The development of reliable protocols for the investigation of Creutzfeldt-Jakob disease. *Neuropathol and Appl Neurobiol* 1994; 20:375-383.
562. Ironside JW, DeArmond SJ. Human prion diseases (Workshop 4). *Brain Pathol* 1994; 4: 313-315.
563. McNaughton H, Will RG. Creutzfeldt-Jakob disease presenting as stroke: an analysis of 30 cases. *Ann Neurol* 1994; 36(2):313.
564. Sutherland K, Barrie C, Ironside JW. Automatic quantification of amyloid plaque formation in human spongiform encephalopathy. *Neurodegeneration* 1994; 3: 293-300.
565. Sutherland K, Barrie C, Ironside JW. Automatic image analysis of PrP plaque formation in human spongiform encephalopathy. *Neuropath Appl Neurobiol* 1994; 20: 518.
566. Sutherland K, Ironside JW. Novel application of image analysis to the detection of spongiform change. *Analytical and Quantitative Cytology and Histology* 1994; 16(6): 430-434.
567. Sutherland K, Rutovitz D, Bell JE, Ironside JW. Evaluation of a novel application of image analysis to spongiform change detection. *Proc IEEE Int Conf in Image Processing, Austin Tx, November 1994, pp 378-381.*
568. Tobias E, Mann C, Bone I, De Silva R, Ironside JW. A case of Creutzfeldt-Jakob disease presenting with cortical deafness. *JNNP* 1994;872-873.
569. Wientjens DPWM, Will RG, Hofman A. Creutzfeldt-Jakob disease: a collaborative study in Europe. *JNNP* 1994; 57:1285-1299.
570. Will RG. Commentary: Gene influences on Creutzfeldt-Jakob disease. *Lancet* 1994; 344:1310-1311.
571. Will RG. Possible Creutzfeldt-Jakob disease in an adolescent. *Weekly Epid Record* 1994; 15:105-106.
572. Will RG, Wilesmith JW. Response to the article: 'Vertical transfer of prion disease' by Lacey and Dealler. *Human Reproduction* 1994; 9(10):1792-1800.

1993

573. Bell JE, Ironside JW. Neuropathology of spongiform encephalopathies in humans. *British Medical Bulletin* 1993; 49(4):738-777.
574. Bell JE, Ironside JW. How to tackle a possible Creutzfeldt-Jakob disease necropsy. *J Clin Pathol* 1993; 46:193-197.
575. Esmonde TFG, Will RG. Transmissible spongiform encephalopathies and human neurodegenerative disease. *BJHM* 1993; 49(6):400-404.
576. Esmonde TFG, Will RG, Slattery JM, Knight R, Harries-Jones R, De Silva R, Matthews WB. Creutzfeldt-Jakob disease and blood transfusion. *Lancet* 1993; 341:205-207.
577. Esmonde TFG, Lueck CJ, Symon L, Duchen LW, Will RG. Creutzfeldt-Jakob disease and lyophilised dura mater grafts: report of two cases. *JNNP* 1993; 56:999-1000.
578. Ironside JW, McCardle L, Hayward PAR, Bell JE. Ubiquitin immunocytochemistry in human spongiform encephalopathies. *Neuropathol and Appl Neurobiol* 1993; 19:134-140.
579. Ironside JW, Barrie C, McCardle L, Bell JE. Microglial cell reactions in human spongiform encephalopathies. *Neuropath Appl Neurobiol* 1993; 19(2): 57.
580. Sawcer SJ, Yuill GM, Esmonde TFG, Estibeiro P, Ironside JW, Bell JE, Will RG. Creutzfeldt-Jakob disease in an individual occupationally exposed to BSE. *Lancet* 1993; 341:642.
581. Turner C, Bell JE, Ironside JW. Localisation of microglia in CNS amyloid plaques: an immunocytochemical and confocal microscopic study. *J Pathol* 1993; 170: 401A.
582. Will RG. Epidemiology of Creutzfeldt-Jakob disease. *British Medical Bulletin* 1993; 49(4):960-970.
583. Will RG. The surveillance of Creutzfeldt-Jakob disease in the United Kingdom. In: *Transmissible Spongiform Encephalopathies. Proceedings of a Consultation on BSE with the Scientific Veterinary Committee of the European Communities held in Brussels 14-15 September 1993.* Eds: Bradley R, Marchant B. pp 143.
584. Windl O, Dempster M, Chambers D, De Silva R, Will RG, Lathe R, Estibeiro P. Slow infections of the central nervous system: the legacy of Dr Bjoern Sigurdsson. ? 1993.

1992

585. Bell JE, Ironside JW, McCardle L, Will RG. Creutzfeldt-Jakob disease – UK Neuropathology Project. *Neuropath Appl Neurobiol* 1992; 18: 302.
586. Brown P, Preece MA, Will RG. 'Friendly fire' in medicine: hormones, homografts, and Creutzfeldt-Jakob disease. *Lancet* 1992; 340:24-27.

587. Esmonde TFG, Will RG. Magnetic resonance imaging in Creutzfeldt-Jakob disease. *Ann Neurol* 1992; 31(2):230-231.
588. Esmonde TFG, Will RG. Creutzfeldt-Jakob disease in Scotland and Northern Ireland 1980-1989. *Scot Med J* 1992; 37:181-184.
589. Esmonde TFG, Will RG. Transmissible Spongiform Encephalopathies and their relationship to human neurodegenerative disease. *B J Hosp Med* 1992; 49(6): 400-404.
590. Ironside JW, Bell JE, McCardle L, Will RG. Neuronal and glial reactions in Creutzfeldt-Jakob disease. *Neuropath Appl Neurobiol* 1992; 18: 295.
591. Ironside JW, Bell JE, Hayward P. Glial and neuronal reactions in Creutzfeldt-Jakob disease. *Clin Neuropathol* 1992; ii: pp226.
592. Will RG. BSE and the spongiform encephalopathies. In: Kennard C, editor. *Recent Advances in Clinical Neurology*. Churchill Livingstone, 1992.
593. Will RG, Ironside JW, Bell JE. Bovine spongiform encephalopathy and risk to health. *BMJ* 1992; 305:53.
594. Will RG. Prions in animals. *Virus & Life* 1992; 4:6-8.
595. Will RG, Esmonde TFG, Matthews WB. Creutzfeldt-Jakob disease epidemiology. In: Prusiner SB, Collinge J, Powell J, Anderton B, editors. *Prion diseases of humans and animals*. New York: Ellis Horwood, 1992: 188-199.
596. Will RG, Matthews WB. Creutzfeldt-Jakob disease epidemiology. In: Prusiner SB, Collinge J, Powell J, Anderton B, editors. *Prion Diseases of Humans and Animals*. Chichester: Proceedings of Prion Diseases in Humans and Animals, London 2-4 September, 1992: 188-199.

1991

597. Bell JE, Ironside JW. Department of Health National Surveillance of Creutzfeldt-Jakob disease. *The Bulletin of the Royal College of Pathologists* 1991; 74:9-10.
598. Will RG. Subacute spongiform encephalopathies. In: Lawson DH, editor. *Current Medicine 3*. Edinburgh: Churchill Livingstone, 1991: 127-143.
599. Will RG. Comment: Slow virus infection of the central nervous system. In: Hayward RD, Quinn NP, Wade JPH, Shorvon SD, editors. *Current Medical Literature: Neurology*. London: Current Medical Literature Ltd, 1991: 67-71.
600. Will RG. Editorial: The Spongiform Encephalopathies. *JNNP* 1991; 54:761-763.
601. Will RG. An overview of Creutzfeldt-Jakob disease associated with the use of human pituitary growth hormone. *Develop Biol Standard* 1991; 75:85-86.
602. Will RG. Is there a potential risk of transmission of BSE to the human population and how may this be assessed? In: Bradley R, Savey M, Marchant B,

editors. Sub-Acute Spongiform Encephalopathies. Dordrecht: Kluwer Academic Publishers for the EEC, 1991: 179-186.

603. Will RG. Diseases of the nervous system. In: Edwards CRW, Bouchier IAD, editors. Davidson's Principles and Practice of Medicine. Edinburgh: Churchill Livingstone, 1991: 811-904.
604. Will RG. Epidemiology of Creutzfeldt-Jakob disease in the United Kingdom. *European J Epid* 1991; 7(5):460-465.
605. Yeung KB, Thomas PK, King RHM, Waddy H, Will RG, Hughes RAC, Gregson NA, Leibowitz S. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. *J Neurol* 1991; 238:383-391.

1990

606. Cousens SN, Harries-Jones R, Knight R, Will RG, Smith PG, Matthews WB. Geographical distribution of cases of Creutzfeldt-Jakob disease in England and Wales 1970-84. *J Neurol Neurosurg Psych* 1990; 53:459-465.
607. Scott PR, Aldridge BM, Clarke M, Will RG. Cerebrospinal fluid studies in normal cows and cases of bovine spongiform encephalopathy. *Br Vet J* 1990; 146:88-90.
608. Will RG. Dementia and Alzheimer's Disease. *Dementia & Alzheimer's disease* 1990;7-12.
609. Will RG. Prion disease (Letter). *Lancet* 1990; 336:369.